**Name of Journal**: *World Journal of Diabetes*

**Manuscript NO:** 48098

**Manuscript Type**: REVIEW

**Bone health in diabetes and prediabetes**

Costantini S *et al*. Bone and diabetes

Silvia Costantini, Caterina Conte

**Silvia Costantini, Caterina Conte**, Department of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, Milan 20123, Italy

**Caterina Conte**, IRCCS Ospedale San Raffaele, Internal Medicine and Transplantation, Milan 20123, Italy

**Silvia Costantini**, Epatocentro Ticino, Lugano 6900, Switzerland

**ORCID number:** Silvia Costantini (0000-0002-3418-9150); Caterina Conte (0000-0001-7066-5292).

**Author contributions:** Both authors equally contributed to this paper with conception and design of the article, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest** **statement:** No potential conflicts of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited Manuscript

**Corresponding author: Caterina Conte,** **MD, PhD, Assistant Professor,** Department of Immunology, Transplantation and Infectious Diseases, Vita-Salute San Raffaele University, via Olgettina 60, Milan 20123, Italy. conte.caterina@unisr.it

**Telephone:** +39-2-36432575

**Received:** April 6, 2019

**Peer-review started:** April 8, 2019

**First decision:** May 9, 2019

**Revised:** June 3, 2019

**Accepted:** July 20, 2019

**Article in press:**

**Published online:**

**Abstract**

Bone fragility has been recognized as a complication of diabetes, both type 1 diabetes (T1D) and type 2 diabetes (T2D), whereas the relationship between prediabetes and fracture risk is less clear. Fractures can deeply impact a diabetic patient’s quality of life. However, the mechanisms underlying bone fragility in diabetes are complex and have not been fully elucidated. Patients with T1D generally exhibit low bone mineral density (BMD), although the relatively small reduction in BMD does not entirely explain the increase in fracture risk. On the contrary, patients with T2D or prediabetes have normal or even higher BMD as compared with healthy subjects. These observations suggest that factors other than bone mass may influence fracture risk. Some of these factors have been identified, including disease duration, poor glycemic control, presence of diabetes complications, and certain antidiabetic drugs. Nevertheless, currently available tools for the prediction of risk inadequately capture diabetic patients at increased risk of fracture. Aim of this review is to provide a comprehensive overview of bone health and the mechanisms responsible for increased susceptibility to fracture across the spectrum of glycemic status, spanning from insulin resistance to overt forms of diabetes. The management of bone fragility in diabetic patient is also discussed.

**Key words**: Bone; Fractures; Type 1 diabetes; Type 2 diabetes; Prediabetes; Diabetes complications; Bone density; Hypoglycemic agents

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Diabetes mellitus, either type 1 or type 2, is associated with increased fracture risk. Diabetic hyperglycemia and insulin resistance underlie functional alterations of bone cells and bone marrow fat that affect several determinants of bone strength, including bone matrix proteins and bone mass, geometry and microarchitecture. Diabetes-related microvascular complications and certain antidiabetic drugs appear to further increase fracture risk, both directly and indirectly. The prevention and management of bone fragility in diabetes includes identification of patients at risk, correction of modifiable risk factors including appropriate choice of antidiabetic drugs and use of antifracture drugs with proven efficacy.

Costantini S, Conte C. Bone health in diabetes and prediabetes. *World J Diabetes* 2019; In press

**INTRODUCTION**

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia leading to serious microvascular and macrovascular complications. In recent years, bone fragility has emerged as a further complication of DM, both Type 1 diabetes (T1D) and type 2 diabetes (T2D). Aim of this review is to provide a comprehensive overview of bone health across the spectrum of glycemic status, spanning from insulin resistance to overt forms of diabetes.

***Insulin and bone***

Insulin is an anabolic hormone central to the regulation of substrate metabolism in key organs and tissues such as skeletal muscle, the liver and adipose tissue[1]. Both osteoblasts and osteoclasts express the insulin receptor. Insulin stimulates osteoclast formation and promotes proliferation, differentiation and survival of osteoblasts, with an overall balance in favor of bone formation[2]. Studies on insulin receptor knockout mice indicate that insulin signaling is necessary for normal bone acquisition[3,4], likely due to the role of insulin in the regulation of bone energy metabolism. In fact, insulin administration increases 18F-fluorodeoxyglucose ([18F]FDG) uptake by bone in mice, which is markedly reduced in mice lacking the insulin receptor in osteoblasts[5]. Furthermore, activation of the insulin receptor in the growth plate of mice fed with a hypercaloric diet stimulates skeletal growth and growth plate chondrogenesis[6]. Osteoblasts also express the Insulin-like growth factor 1 (IGF-1) receptor[7]. IGF-1 binds both to the IGF-1 receptor and, with lower binding affinity, to the insulin receptor, thus triggering the insulin signaling pathway and exerting osteoanabolic actions.

***DM***

Depending on the pathogenic mechanism(s) causing chronic hyperglycemia, DM is classified into few main general categories. T1D is distinguished by absolute insulin deficiency due to destruction of pancreatic beta-cells on an autoimmune or idiopathic base. Latent autoimmune diabetes in adults (LADA) is a less common form of autoimmune diabetes that arises in the adult age and is characterized by circulating islet autoantibodies and insulin independence at diagnosis. In T2D, insulin resistance leading to compensatory increase of insulin secretion causes progressive worsening of beta cell function that eventually results in relative insulin deficiency and hyperglycemia. Other forms of DM include monogenic forms (*e.g.,* maturity onset diabetes of the young, MODY), gestational diabetes, and secondary forms either associated with conditions that affect insulin secretion (*e.g.*, pancreatic diseases) or certain drugs (*e.g.*, glucocorticoids and immunosuppressants after organ transplantation). This review will focus on the main diabetes categories, *i.e.* T1D and T2D, as well as on those alterations of glucose metabolism collectively identified as prediabetes[8].

**Diabetes and prediabetes: clinical impact on bone**

***Fracture risk in T1D***

Fracture risk is increased in T1D, with a 2- to 6-fold higher risk of fracture as compared with non-diabetic subjects, the risk being greatest in T1D women[9,10]. In a recent analysis that assessed the determinants of fracture risk in T1D adult patients, nearly half of the subjects reported at least one fracture after diabetes diagnosis[11]. Older age, longer T1D duration, age < 20 years at diagnosis and family history of osteoporosis or osteopenia were associated with fracture occurrence.

***Fracture risk in T2D and prediabetes***

Individuals with T2D have a 1.2- to 3-fold higher risk of fracture as compared with non-diabetic subjects, particularly for hip fractures[9,12], but also for upper arm and ankle fractures[13]. Fracture risk appears to be greater in those with a body mass index (BMI) < 30 kg/m2 as compared with obese individuals[14], and not to significantly differ by gender[9,15]. Diabetes duration longer than 10 years, low levels of physical activity, use of insulin and systemic corticosteroids and increasing age are also associated with higher fracture risk in T2D[14]. Falls represent another risk factor for fractures, especially in diabetic women[14,16,17]. The association between diabetes, especially T2D, and increased risk of falls is well recognized[18,19] and mainly attributed to diabetes related complications such as therapy-induced hypoglycemic episodes, impaired muscle strength due to sarcopenia, retinopathy-related impaired vision, peripheral artery disease and neuropathy[20,21]. As in a vicious circle, fractures may lead to imbalance, alterations in posture and decreased muscle strength, eventually reducing physical performance and further increasing the risk of falls[22]. Predictive factors of falls and their contribution to fracture risk in T1D patients have not been clearly identified[23].

Despite a clear association between T2D and increased fracture risk[9,19,24], evidence supporting an association between prediabetes and fracture risk is inconsistent. Observations in adolescents suggest that insulin resistance may be detrimental for bone development through puberty, independent of body composition and the level of physical activity[25]. However, no association between insulin resistance and fracture risk was evident after adjustment for BMI and bone mineral density (BMD) in a large cohort of elderly subjects[26]. These findings are consistent with studies that found no statistically significant difference in fracture risk between subjects with or without prediabetes[27,28], but are in contrast with those reporting an association between prediabetes, adjusted for BMI and/or BMD, and lower fracture risk[29].

***Assessment of fracture risk in diabetes***

Schwartz and colleagues analyzed data from nearly 17,000 older community-dwelling men and women, and found that, for a given T-score and age or FRAX® score (the most widely used fracture risk index), subjects with diabetes had a higher fracture risk than those without diabetes[30]. Similarly, Giangregorio *et al*[31] found that FRAX underestimates the risk of major osteoporotic and hip fractures in individuals with diabetes. Recently, four options have been assessed to enhance the performance of FRAX in patients with DM (using rheumatoid arthritis as a proxy for the effects of DM, trabecular bone score [TBS]-adjustment, reducing the femoral neck T-score input by 0.5 SD, increasing the age input by 10 years)[32]. Although each correction improved the performance of the FRAX tool in predicting fracture risk, no single method was optimal for all fracture outcomes and durations of diabetes.

**DIABETIC BONE DISEASE-PATHOPHYSIOLOGY**

Several factors might be responsible for the increased fracture risk in diabetic patients. Diabetes-related changes affect bone strength, which in turn depends on different and complex components, *i.e.* BMD, bone microarchitecture and its microenvironment and material properties.

***Bone cells***

Cellular and molecular components cross-talk to maintain skeletal integrity in an ­intricate balance that can be altered in DM. It is important to understand alterations in these components, as they have also direct clinical consequences and may represent targets for clinical interventions. Structural elements with a role in physiologic bone formation include support cells like osteoblasts and osteocytes, remodeling cells known as osteoclasts, and non-cellular components like osteoid (hydroxyapatite, collagen, non-collagen-structural proteins) and mineral salts deposited within the matrix. Mesenchymal stem cells (MSC), *i.e*., the osteoblast precursors, may also differentiate into adipocytes. The fate of MSCs depends on a fine balance between the WNT signaling pathway, which promotes osteogenesis, and the peroxisome proliferator-activated receptor-γ (PPAR-γ) pathway, which promotes adipogenesis[33]. An imbalance between these pathways may result in one cell type predominating over the other. Along with the bone-resorbing osteoclasts, osteoblasts are involved in a fundamental process that lasts the whole human life, bone remodeling, wherein old bone is substituted with new bone to maintain bone strength and mineral homeostasis, and to repair microdamage[34].

***Osteoblasts in T1D***

Preclinical studies[25] documented alterations in transcription of osteoblasts promoting genes, in particular Runx2, which is involved in MSC differentiation into pre-OBs and in the regulation of bone matrix protein genes. Some preclinical studies suggested that Runx2 is downregulated by hyperglycemia[35,36], although other studies reported no modification[37,38]. The *Wnt/beta catenin* gene, which is known to promote OB differentiation, is also downregulated[39]. In T1D, low levels of IGF-1, which promotes differentiation of MSCs into OBs[40,41] and bone mineralization[42], may also contribute to reduced bone formation. It is also known that serum from T1D patients decreases collagen production in human OBs when used as a culture medium[43]. Moreover, individuals with T1D have low levels of parathyroid hormone (PTH)[44], which in normal conditions prevents OB apoptosis[45], improves bone density and increases mineralization and enhances, synergistically with IGF-1, osteoblast differentiation into osteocytes[46]. An increase in circulating levels of proinflammatory cytokines such as TNF-a, IL1 and IL6 due to hyperglycemia[47,48], may impair OB proliferation and differentiation *in vitro*[49-53], or even stimulate OB apoptosis[54,55], while inhibiting bone healing *in vivo*[56]. Overall, the evidence suggests that an impairment on OB function and survival may be responsible for reduced bone formation in T1D.

***Osteoblasts in T2D***

Few studies on OBs from T2D subjects are available. Postmenopausal women with T2D were reported to have higher levels of OB precursor cells than BMI-matched non-diabetic controls. OBs were more immature compared with controls, and Dickkopf-related protein 1 (DKK-1), a regulator produced by bone marrow stromal cells that inhibits OB maturation, was increased[57]. Thus, it appears that individuals with T2D have increased levels of immature OBs, which may explain lower bone quality and higher BMD.

***Osteocytes in T1D***

In mouse models of T1D, a reduction in osteocyte density and number, and an increase in apoptosis have been reported[58-60]. Sclerostin, an osteocyte-derived protein that inhibits bone formation[61,62] and stimulates OB apoptosis[63], is elevated in adults with long-standing T1D[64] prediabetes[65], or T2D[66]. Surprisingly, however, a large Danish retrospective study of T1D patients found that T1D patients with higher serum levels of sclerostin had a lower incidence of bone fractures[67].

***Osteocytes in T2D and prediabetes***

As mentioned, osteocyte-derived sclerostin is elevated in adults with T2D and prediabetes[65,66]. In T2D, there is a direct correlation between sclerostin levels, disease duration and glycemic control, and an inverse correlation with bone turnover markers[66,68]. Anti- sclerostin antibodies increased bone mass in diabetic rats[69]. This finding is of particular interest, as an anti-sclerostin monoclonal antibody (romosozumab) is now available for the treatment of osteoporosis in humans[70].

***Osteoclasts in T1D***

In physiological conditions, the OB-derived receptor activator of nuclear factor kappa-Β ligand (RANKL), promotes the differentiation and activation of osteoclasts through the receptor RANK on osteoclast surface. This process is inhibited by osteoprotegerin (OPG), also produced by OBs, which binds to RANKL thereby preventing its interaction with RANK. Patients with T1D and poor glycemic control exhibit more active bone resorption. Consistently, the analysis of peripherally detected osteoclasts in patients with T1D showed a lower sensitivity to inhibitory factors such as OPG[71]. An increased *OPG* gene expression compared to healthy controls has also been reported[72], possibly to compensate for the lower sensitivity to OPG. Other *in vitro* studies, however, showed a reduction in RANKL and its cellular actions in hyperglycemic environments[73] , which could indicate a limited role of RANKL and OPG in the pathogenesis of bone alterations in DM. Finally, a higher concentration of markers of osteoclastic activity (cathepsin K, tartrate-resistant acid phosphatase [TRAP], C terminal telopeptide) has been observed in insulinopenic mice[74,75], although this increase was significant only in the case of severe or long-lasting diabetes. This variability in osteoclastic activation suggests that disease severity and duration may influence the degree of diabetes-induced bone resorption[76,77] .

***Osteoclasts in T2D***

High glucose levels inhibit osteoclast differentiation and suppress matrix degradation by osteoclasts in animal models of T2D[78]. Accordingly, circulating osteoclast precursors were found to be increased and more immature in T2D postmenopausal women compared with BMI-matched healthy controls, possibly due to lower RANKL levels[57]. It may be speculated that a lower level of maturation compromises OC activity, leading to decreased bone resorption resulting in higher BMD in T2D.

***BMD***

**BMD in T1D**: Low BMD is reported in nearly all studies involving T1D patients of any age compared to non-diabetic controls[79]. The reduction in BMD worsens with longer disease duration[80], poor glycemic control, early age of onset of T1D, and higher insulin dosage[81]. Furthermore, T1D adult patients with microvascular complications have lower BMD than those without microvascular disease[81-86], suggesting a role for bone vascularization in the pathogenesis of diabetic bone disease. Children and adolescents withy T1D have smaller cross-sectional areas and weaker bones despite an increase in bone formation markers, suggesting impaired osteoblast activity during growth[87]. It is likely that an inadequate peak bone mass is reached at the end of the skeletal maturation due to low levels of IGF-1 and the catabolic effects of uncontrolled hyperglycemia during critical growth period[88,89]. Consistently, patients with onset of diabetes before age 10 years reach a lower than average mean near-adult height, adult height being inversely correlated with glycemic control[90].

Altered vitamin D and calcium metabolism due to hyperglycemia may further contribute to reduced BMD in T1D[91]. Reduced BMD, however, might not be the only factor contributing to increased fracture risk. Recent observations suggest that, opposite to what one would expect, BMD does not worsen over time in patients with T1D as compared with nondiabetic individuals[92].

**BMD in T2D and prediabetes:** Subjects with T2D generally have higher BMD as compared with healthy controls, with significant differences of 0.04 (95%CI: 0.02, 0.05) at the femoral neck, 0.06 (95%CI: 0.04, 0.08) at the hip and 0.06 (95%CI: 0.04, 0.07) at the spine[93]. As insulin is known to exert anabolic effects on bone, high circulating insulin levels may explain the observed increase in BMD in T2D[94]. Accordingly, some studies indicate a positive association between circulating insulin levels and BMD, independent of BMI[95-97]. However, in most studies the positive association between insulin levels or indices of insulin resistance and BMD was lost after adjusting for BMI[26,98-101], implying that the increase in BMD observed in insulin resistant states is mediated by body mass. In fact, obesity has long been considered to be protective towards osteoporosis and osteoporotic fractures, being associated with increased mechanical load stimulating bone formation[102], androgens-to-estrogens conversion in adipose tissue, lower serum levels of sex hormone binding globulin (SHBG)[103], increased circulating leptin[104] and insulin growth factor, and hyperinsulinemia[99]. Recent findings challenge this belief, suggesting that even though BMD increases with body weight, this cannot compensate for obesity-associated greater impact forces during falls. Data from a multiethnic cohort of nearly 2000 pre- or perimenopausal women indicate that higher BMI is associated with higher BMD, but also with lower composite strength indexes[105]. Conflicting data on the association between obesity and fracture risk, with earlier studies demonstrating a protective effect[106-109] and more recent studies indicating an increase in risk[110-114], suggest that BMI is not the only relevant factor in this context, and that body composition and fat distribution may also play a role[115]. Elevated waist circumference and waist-to-hip ratio have been associated with an increased hip fracture risk in a large prospective cohort study[116]. In obese Chinese women, increased fat mass and percent body fat were positively associated with BMD, whereas increased central fat was inversely associated with BMD[117]. Accordingly, visceral adiposity has been associated with increased risk of both vertebral and non-vertebral fractures[118,119]. Central adiposity reflects the amount of visceral adipose tissue (VAT), which is more cellular, vascular, innervated and characterized by the presence of more inflammatory and immune cells, lesser pre-adipocyte differentiating capacity and higher proportion of large adipocytes as compared with subcutaneous adipose tissue (SAT)[120]. VAT is tightly correlated with insulin resistance[121], which, together with low-grade chronic inflammation, possibly mediates the relationship between VAT and increased fracture risk.

In Korean men diagnosed with prediabetes using an oral glucose tolerance test, no significant difference in BMD T-score was found as compared with subjects having normal glucose metabolism[122]. Despite no difference in total body BMD between prepubertal overweight children with prediabetes *vs* non-prediabetic controls (as assessed by OGTT)[123], total body bone mineral content (BMC) was found to be significantly lower in prediabetic children. Inverse associations were found between BMC and markers of insulin resistance and inflammation (C-reactive protein).

***Bone turnover***

Bone turnover may be assessed by measuring bone turnover markers (BTMs), which reflect the bone resorption and formation processes.

**Bone turnover in T1D**: In general, both T1D and T2D are considered as states of low bone turnover. Different studies have shown that worse glycemic control is associated with lower bone turnover markers in T1D[124-126], suggesting a negative effect of hyperglycemia on bone turnover. More specifically, patients with T1D exhibit higher sclerostin levels and lower C-terminal telopeptide of type I collagen (CTX) and osteocalcin levels as compared with non-diabetic controls[127].

**Bone turnover in T2D and prediabetes:** Bone turnover markers are generally reduced in patients with T2D[126,128,129], to a greater extent than patients with T1D[130]. However, not all studies yielded consistent findings. Osteocalcin and CTX are the BTMs most consistently found to be lower in T2D and patients with as compared with subjects without diabetes, whereas sclerostin and osteoprotegerin are generally elevated (Table 1). Conflicting findings have been reported for other markers but, overall, the evidence seems to point towards a suppression of bone formation and bone resorption, both in prediabetes and T2D. Histomorphometric evaluation of bone tissue biopsies from T2D patients confirmed reduced bone turnover[131,132]. The suppression of bone turnover reported in T2D patients is associated with higher risk of vertebral fractures[133,134], independent of BMD. This is consistent with the concept that the impairment in bone strength in T2D is due to impaired material properties, which may be caused by low bone turnover, as well as by elevated concentrations of advanced glycation endproducts (AGEs)[135].

Fewer studies have assessed bone turnover in prediabetes. Impaired fasting glucose (IFG) was associated with lower osteocalcin[128], CTX and N-amino terminal propeptide of T1D procollagen (P1NP)[136,137] in women, and lower CTX and P1NP in men[136], suggesting that, similar to T2D, prediabetes is associated with reduced bone turnover.

***Increased bone marrow adiposity***

Bone marrow adipose tissue (MAT) has gained increasing attention in recent years as a single anatomic entity, together with its relations with various clinical conditions, including diabetes. MAT consists of MSC-derived adipocytes located within the bone marrow niche. The distribution of MAT around the skeleton is not homogenous, and regulation of marrow adipose depots varies at different skeletal sites. While peripheral depots of MAT (also termed constitutive MAT) rarely change, MAT depots at more central sites (*e.g.,* spine, pelvis and sternum, proximal regions of the long bones) are more diffuse within the red marrow and may increase or decrease in response to environmental or pathological factors (regulated MAT)[138]. Interestingly, hyperglycemia increases the expression of *PPAR* genes, which stimulates differentiation of MSC into bone marrow adipocytes[139]. Similarly, the antidiabetic PPARγ agonists thiazolidinediones (TZDs) are thought to increase fracture risk through promotion of marrow adipogenesis at the expense of osteogenesis[140](Figure 1). Until recently, MAT was thought to be just a reserve of adipose tissue, negatively associated with hematopoiesis, but its complete function has just begun to be revealed. *In vivo* studies using magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) or computed tomography (CT) to assess MAT quantity and composition have helped understand the mechanisms of increased skeletal fragility and metabolic risk associated with several clinical conditions, including diabetes[141].

**MAT in T1D:**In animal models of T1D, hyperglycemia is associated with increased marrow adiposity and bone loss[37,38,142], whereas no differences in MAT were identified between male patients with T1D and healthy controls[143,144], and neither duration of disease nor glycemic control were related to bone marrow adiposity. This lack of association between MAT and T1D was confirmed in young women with T1D compared with healthy controls[145]. Irrespective of the presence of diabetes, in young women MAT was inversely associated with BMD[145]. Carvalho and colleagues showed that MAT quantity and lipid composition (saturated and unsaturated lipids) were similar between male T1D subjects and controls[144]. There was, however, a significant inverse correlation between MAT saturated lipids and BMD.

**MAT in T2D**: In T2D men participating in the Osteoporotic Fractures in Men (MrOS) Study, a large epidemiological study of nearly 6,000 men, vertebral MAT was increased as compared with nondiabetic controls, and inversely associate with BMD[146]. Although no differences were detected in total MAT content in postmenopausal women, those with T2D and previous fractures had the lowest MAT lipid unsaturation and highest MAT saturation levels independent of age, race, and BMD, highlighting the importance of MAT composition in addition to the degree of marrow adiposity[147]. Furthermore, gender-related differences have been reported in the association between MAT and visceral adipose tissue (VAT)/subcutaneous adipose tissue (SAT) volumes or BMI. While in obese or diabetic women MAT is associated with VAT and SAT[148,149], no such association was found in older men[150]. In men, a negative association between MAT and DXA-derived BMD of femoral neck and total hip was reported. Data on MAT in pre-diabetes is scanty, but a potential relation between hyperglycemia and MAT has been suggested[151].

**ADVANCED GLYCATION END PRODUCTS-BONE MATRIX IN DIABETES**

AGEs are protein or lipid complexes formed through non-enzymatic reactions in the presence of high sugar levels. Their accumulation is thought to play a role in aging and some degenerative diseases[152]. In *in vitro* studies, AGEs deposits have been demonstrated in bone matrix, where they may exert a direct toxic effect on OBs[153]. AGEs inhibit bone remodeling and indirectly up-regulate the production of interleukin 6 (IL-6)[154], a catabolic factor that attenuates OBs activity[53] and vascular endothelial growth factor A (VEGF-A) by osteocytes, inducing also their apoptosis[155].

**AGEs in T1D**: In murine models of T1D, the AGE pentosidine (PEN) in bone is significantly increased, this increase being paralleled by an impairment in bone mechanical properties[156]. Similarly, PEN levels in bone biopsies from fractured T1D patients were higher than in controls[80], and circulating PEN levels are associated with prevalent fractures in T1D[157]. Carboxymethyllysine (CML), another type of AGE that correlates with fracture risk[158], is increased in mouse models of T1D and inversely associated with bone strength[159].

**AGEs in T2D and prediabetes:** Bone strength in T2D postmenopausal women is reduced as compared with non-diabetic controls, and this reduction appears to be associated with increased AGE accumulation, as indirectly estimated by skin autofluorescence (SAF)[160]. Consistently, increased urinary or serum PEN levels have been associated with greater fracture risk in T2D[161,162]. To the best of our knowledge, no data are available on AGEs and bone health in prediabetes.

***Bone geometry and microarchitecture***

Bone geometry and microarchitecture contribute to bone strength. Tools such as high-resolution peripheral quantitative computed tomography (HR-pQCT), micro-magnetic resonance (μ-MRI) and TBS acquired through dual-energy X-ray absorptiometry (DXA) are available to study bone structure in diabetes[163,164], offering enough resolution to assess microarchitecture and providing indirect indexes of bone quality.

**Bone geometry and microarchitecture in T1D:** In rodent models of T1D, deletion of the insulin receptor from OBs at different stages of maturation leads to anomalous trabecular architecture and higher bone fragility[3,4]. In adults with T1D, trabecular bone quality is lower as compared with non-diabetic age-, BMI-, and sex-matched controls and is negatively associated with insulin resistance, as assessed by the hyperinsulinemic euglycemic clamp[165]. Studies using HR-pQCT demonstrated higher cortical porosity, thicker trabeculae and larger spacing between trabeculae in T1D patients with microvascular complications, compared to those without, and in T1D patients compared with matched non-diabetic controls[166]. Similar findings were reported using μ-MRI[167]. Moreover, using μ-CT in T1D subjects without vascular complications, worse bone quality was found in those who did experience fractures as compared with those who did not[166]. An insufficient peak bone mass at the end of skeletal maturation may result in smaller and shorter bones, a geometry that could favor bone fragility[130]. However, the contribute of altered geometry and defective trabecular and cortical bone to the increased risk of fracture in T1D is yet to be clarified.

**Bone geometry and microarchitecture in T2D and prediabetes:** The increased fracture risk in T2D may be related to distorted bone microarchitecture, especially in cortical bone[168-170].

Bone micro-indentation allows measuring the bone material strength index (BMSi), which estimates the resistance to crack propagation in bone[171]. BMSi is reduced in patients with T2D as compared to healthy controls[88,93], suggesting a lower resistance to fractures. Increased cortical porosity has been identified as a possible causative factor. Patients with T2D have higher porosity in trabecular bones, as assessed by MRI[170]. Studies using HR-pQCT confirmed a similar trend in porosity. Deficits in cortical bone of T2D patients were more marked in patients with previous fractures compared to those without[169], or present only in T2D patients with microvascular complications compared with patients without complications[169]. In a cross-sectional analysis of nondiabetic postmenopausal women, higher levels of insulin resistance were associated with lower cortical bone volume, independent of age and weight[172]. Consistently, female obese late-adolescents had worse trabecular bone microarchitecture at the radius and tibia as compared with non-obese controls, as well as lower bone volume and estimated bone strength[173]. T2D diabetes and insulin resistance are almost invariably associated with obesity and increased central adiposity, which reflects increased VAT. Studies that explored the relationship between VAT and bone microarchitecture suggest a possible detrimental effect of VAT on bone microarchitecture. Studies have reported a negative impact of VAT on bone microarchitecture, as suggested by a negative association between central adiposity measures and TBS[174,175]. Furthermore, a negative effect of VAT on femoral cross-sectional area, cortical bone area and bone strength indexes has been reported[176]. On the other hand, higher VAT was associated with improved microarchitecture with the exception of higher cortical porosity at the distal radius in the Framingham osteoporosis study[177]. However, this association lost significance after adjustment for BMI or weight, suggesting that the effects of VAT may not have a substantial effect on the skeleton independent of BMI or weight. In non-diabetic men at the age of peak bone mass, insulin resistance (as assessed by HOMA-IR) was found to be inversely associated with trabecular and cortical bone size, independent of body composition[178]. Overall, these data suggest a detrimental role of hyperinsulinemia on bone microarchitecture and geometry. Central adiposity might have a negative effect on bone microarchitecture, but this possibility needs to be further explored.

***Vascular disease: microangiopathy***

Diabetic microvascular complications such as retinopathy and neuropathy may indirectly potentiate the fall risk, impairing vision or physical perception. Diabetic microangiopathy may involve all organs, including bone, possibly contributing to bone fragility. Histomorphometric assessments found microangiopathy in 82% of bone biopsy specimens from diabetic patients, and a concomitant reduction of bone marrow capillaries[179]. To date, there is no other direct evidence of bone vascular alteration in humans. In mouse models of T1D, administration of an angiogenic factor to ovariectomized mice led to improvements in bone quality[180]. As mentioned, reduced trabecular BMD, cortical BMD, thinner trabeculae and cortex were reported in T1D patients with known vascular complications, as opposite to T1D patients without complications and non-diabetic controls[166]. Similarly, in a cross-sectional study that assessed peripheral bone microarchitecture, bone strength and bone remodeling in T2D patients with or without diabetic microvascular disease only T2D patients with established microvascular disease displayed lower cortical volumetric BMD and cortical thickness and higher cortical porosity at the radius compared to controls without microvascular disease[181]. Impaired microvascular circulation might lead to hypoxia, which in turn may lead to enhanced adipogenesis within the bone marrow and downregulation of OB differentiation[182].

***Pharmacological treatments for diabetes***

*Metformin*. Metformin is widely prescribed for the management of T2D, being recommended as the first-line treatment by international guidelines[8,183]. It reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing peripheral glucose disposal[184]. Metformin has been shown to promote the osteogenic differentiation of adipose-derived MSC, and in general to exert pro-osteogenic effects in preclinical studies[185-188]. Clinical observations indicate that metformin has a neutral[28,189] or even a favorable effect on fracture risk[12,190,191].

**Glucagon-like peptide-1 (GLP-1) receptor agonists (RA):** GLP-1 RAs (liraglutide, exenatide, lixisenatide, dulaglutide, semaglutide) are recommended as the best choice for a second agent when combination treatment is needed to achieve glycemic control in patients with T2D in whom atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease predominates[8,183]. By activating the GLP-1 receptor, GLP-1 RAs slow gastric emptying, suppress glucagon secretion while also stimulating glucose-induced insulin secretion[192]. These effects result in the suppression of hepatic gluconeogenesis and increased peripheral glucose disposal. *In vitro*, activation of GLP-1 receptors promotes differentiation of MSC into osteoblasts[193] and inhibits osteoblast apoptosis[194], suggesting an anabolic effect on bone. Studies in rats support these findings[195]. Of note, in animal models of T1D administration of liraglutide significantly improved bone strength and reduced collagen degradation in the bone matrix, although no changes in trabecular no cortical microarchitecture were observed[196]. Case-control studies and metanalyses of population-based studies and randomized clinical trials including patients with T2D treated with GLP-1 RAs indicate no effect on fracture risk[197-199]. However, evidence exist that different GLP-1 RAs may exert opposite effects on fracture risk, which appears to increase or decrease in patients treated with exenatide or liraglutide, respectively[200]. Furthermore, liraglutide was reported to prevent a reduction of BMC after weight loss in obese nondiabetic women, although BMD was not affected[201,202].

**Dipeptidylpeptidase 4 (DPP4)-inhibitors:** DPP4-inhibitors (sitagliptin, linagliptin, saxagliptin,vildagliptin, alogliptin, *etc*.) exert their action by inhibiting the enzyme DPP-4, which is responsible for the rapid degradation of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and GLP-1, thereby enhancing glucose-induced insulin secretion[203]. Preclinical studies indicate a possible anti-osteoclastogenic and anti-resorptive effect of DPP4-inhibitors[204,205]. Clinical data support a neutral[189,206,207] or even favorable[208,209] effect of DPP4-inhibitors on fracture risk. In particular, alogliptin may be associated with a lower risk of bone fracture compared with placebo and other drugs in the same class[210].

**Sodium-glucose cotransporter 2 (SLGT2) inhibitors**: By inhibiting the renal SGLT2, these drugs (empagliflozin, dapagliflozin, canagliflozin) reduce glucose reabsorption in the kidney, thus increasing urinary glucose excretion and decreasing blood glucose[211]. Associated increases in serum phosphate may lead to changes in PTH and fibroblast growth factor 23 (FGF23) that could affect bone metabolism[212]. Along with GLP-1 RAs, SGLT2 inhibitors are recommended as the best choice for a second agent when combination treatment is needed to achieve glycemic control in patients with T2D in whom atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease predominates[8,183]. Initial reports of increased frequency of bone fractures associated with SGLT2 inhibitors treatment, particularly with canagliflozin, raised concerns about the skeletal safety of these compounds[213]. Furthermore, increased bone turnover and reduced total hip BMD have been reported in patients with T2D treated with canagliflozin[214]. Nevertheless, recent population studies and metanalyses including several thousands of patients consistently failed to demonstrate an association between SGLT2 inhibitor treatment and increased fracture risk in patients with T2D[215-219].

**Sulfonylureas and glinides**: Sulfonylureas (*e.g.,* glimepiride, gliclazide, glybenclamide) and glinides (*e.g.,* repaglinide) stimulate glucose-independent insulin secretion by binding to specific sites at the β-cell membrane[220, 221]. It has been postulated that sulfonylureas do not affect bone directly, but may increase fracture risk by inducing higher rates of hypoglycemic events[222]. Studies that assessed the effect of sulfonylureas and glinides on fracture risk yielded conflicting results, with most studies indicating increased risk[28,189,223-225], but also no effect[191] even decreased risk[12].

**Thiazolidinediones (TZDs)**: TZDs (rosiglitazone, pioglitazone) are insulin-sensitizing agents that exert their action by activating the peroxisome proliferator-activated receptor γ (PPARγ)[226]. Besides enhancing peripheral insulin sensitivity and suppressing hepatic glucose production, activation of PPARγ stimulates adipogenesis and suppresses osteoblastogenesis, thereby reducing the osteoblast pool in the bone marrow[227]. A detrimental effect of TZDs on bone health has been consistently shown. In a cohort study including more than 5000 patients with T2D, current use of TZDs was associated with increased hip fracture risk[190]. Treatment with pioglitazone significantly increased fracture risk compared with placebo in a randomized double-blind, placebo-controlled study[228]. The increase in risk has been confirmed in population-based studies[189] and metanalyses[229], although the impact on bone seems to be more pronounced in women than in men[190,229].

**Insulin in T1D:** Insulin is the pillar of T1D treatment. As previously discussed, insulin exerts anabolic effects on bone. Intensive insulin treatment has been associated with increased BMD in patients with T1D[82]. Consistently, no association between insulin treatment and single nor multiple fractures was found in a recent study that assessed risk factors for fragility fractures in T1D[230].

**Insulin in T2D:** Insulin treatment in patients with T2D is initiated when disease progression overcomes the effect of non-insulin agents[8,183]. Thus, patients with T2D started on insulin generally have longstanding diabetes, and may have developed serious complications such as retinopathy-related impaired vision, peripheral artery disease and neuropathy, which in turn are risk factors for falls[20,21]. Insulin use is associated with a 1.4- to 2-fold increase in fracture risk as compared with no insulin use[189,231], and with a 1.6-fold increase in risk as compared with metformin monotherapy[232]. However, not all studies point towards a negative effect of insulin on fracture risk[12,191]. The association between insulin and increased fracture risk despite the anabolic effects of insulin on bone is likely due to the increased risk of falls and hypoglycemic episodes associated with insulin treatment[222].

***Surgical treatments for diabetes***

**Pancreas and islet transplantation in T1D:** Beta cell replacement through pancreas or pancreatic islet transplantation is the only currently available cure for T1D in humans, with pancreas transplantation being more often associated with insulin independence and longer graft function. Successful pancreas transplantation provides physiological insulin repletion, without the risk of hypoglycemia associated with exogenous insulin administration. Evidence exists that combined pancreas-kidney transplantation leads to improvements in BMD[233], and that fracture rates in patients with T1D are lower after transplantation with a simultaneous pancreas–kidney compared with kidney transplantation alone[234], suggesting that T1D remission by pancreas transplantation favorably impacts fracture risk. However, individuals with T1D undergoing pancreas-kidney transplantation also have end-stage renal disease, which strongly affects bone health. A study assessing the effect of diabetes remission following pancreas transplantation alone on bone health in individuals with T1D and preserved kidney function is currently ongoing (NCT03869281).

**Metabolic surgery for T2D diabetes:** Metabolic surgery is now included as a treatment option for appropriate candidates with T2D[8,235]. Patients undergoing metabolic surgery experience rapid and massive weight loss, which translates into several metabolic benefits, but may be detrimental to bone health. Most available data relate to the Roux-en-Y gastric bypass (RYGB), a restrictive procedure that also involves a malabsorptive component. Sleeve gastrectomy (SG), which has now overcome RYGB and has become the most common bariatric procedure worldwide[236], is a restrictive procedure. Other bariatric procedures, such as the malabsorptive biliopancreatic diversion and the restrictive laparoscopic adjustable gastric banding (LAGB), are being gradually abandoned. Available data indicate that fracture risk after bariatric surgery varies depending on the bariatric procedure, being lowest in patients undergoing LAGB[237] and greatest in those undergoing malabsorptive procedures[238-241], and increases with time after surgery[237,239-242]. However, weight loss-related reductions in BMD have even been reported 6-12 months after minimally invasive bariatric procedures not involving resection of the stomach and/or intestine, such as use of the intragastric balloon or an intraluminal liner implanted into the small intestine[243,244]. Mechanisms underlying the negative effects of bariatric surgery on bone health may involve nutritional factors, mechanical unloading, hormonal factors, and changes in body composition and bone marrow fat[245]. To the best of our knowledge, no studies have specifically addressed the issue of diabetic bone disease in patients with T2D undergoing bariatric surgery.

**PERSPECTIVES: POSSIBLE PREVENTIVE AND THERAPEUTIC APPROACHES**

Modifiable risk factors for fracture, including factors that affect fall risk and glycemic control should be tackled to reduce fracture risk, although no prospective studies are available to show the antifracture efficacy of preventive lifestyle and/or treatment strategies. Drugs shown to be associated with increased fracture risk in T2D, such as insulin and TZDs[231,232,246] should be avoided, when possible. Strict monitoring should be implemented for T2D patients undergoing bariatric surgery in order to prevent nutritional deficiencies that could worsen weight loss-associated bone loss.

Several alterations in calcium homeostasis have been described in diabetic patients, including reduced intestinal calcium absorption and renal tubular calcium reabsorption, and impaired vitamin D synthesis[247]. It is also recognized that individuals with diabetes, both T1D and T2D, have lower vitamin D levels as compared with non-diabetic controls[248,249]. Overall, these alterations may negatively impact calcium homeostasis and bone mineralization. International guidelines recommend vitamin D supplementation for the prevention and/or treatment of osteoporosis and osteoporotic fractures in men and postmenopausal women[250-252], although recent findings bring into question the efficacy of vitamin D supplementation in preventing fractures or falls, or improving BMD[253]. Vitamin D supplementation was shown to increase bone formation markers[254] and reduce bone resorption markers[255] in postmenopausal women with T2D, not to affect bone turnover markers in patients with T2D and chronic kidney disease[256], and to preserve femoral neck BMD in men with prediabetes[257]. Few data are available about the effect of the use of osteoporosis medications in patients with diabetes.

Stemming from some positive preclinical results[258], few recent human studies have focused the attention on nutrients containing antioxidants such as resveratrol, providing encouraging results in terms of on bone density and on bone loss prevention in obese patients[259] and patients with T2D[260,261] have been reported.

Recently, hyperbaric therapy[262,263] has been shown to promote bone regeneration in animal models of diabetes, but further studies are needed to clarify whether this could be an effective approach in humans.

Raloxifene, a second generation selective estrogen receptor modulator (SERM) indicated for the prevention and treatment of postmenopausal osteoporosis[264], was shown to improve bone material properties (femoral toughness) in diabetes-prone rats[265]. In postmenopausal women, raloxifene may decrease the bone resorption marker NTX and it has been speculated that it might improve bone quality by reducing AGEs, although no information is available on the effect on reliable bone quality indicators or relevant clinical outcomes such as fracture risk[265]. In a pilot study that assessed the skeletal effects of a third generation SERM, bazedoxifene, in postmenopausal women with T2D, all bone resorption markers decreased significantly after 12 weeks of treatment. Homocysteine and pentosidine, which were used as bone quality markers in this study, were not affected[266].

Little is known about osteoporosis therapies in T1D young patients. As T1D usually manifests in young individuals, it is important to remember that caution must be taken in women during reproductive age, as bisphosphonates are stored and released from bones for long time and may affect fetal skeletal ossiﬁcation. In elderly, postmenopausal, osteoporotic obese women with T2D treated with long-term bisphosphonates, no difference in spine BMD but a significantly greater decline in BMD in regions of the hip, femoral neck, and forearm were observed as compared with non-diabetic controls[267]. However, the efficacy of these medications must be assessed based on clinically relevant outcomes. Despite being a condition of reduced bone turnover, epidemiological data indicate that diabetes (either T1D or T2D) was shown not to reduce the antifracture efficacy of antiresorptive drugs, which also reduce bone turnover[268].

In a large study on the efficacy of recombinant PTH (rhPTH 1-34, teriparatide), similar reduction in nonvertebral fracture incidence and increase in BMD were observed in postmenopausal osteoporotic women with or without T2D[269].

Denosumab is a RANKL-specific antibody indicated as osteoporosis treatment known to increase particularly cortical BMD. This property might be of particular value, as cortical compartment is the most involved in the diabetic bone. A phase 2 clinical trial to assess the skeletal effects of denosumab in T2D is ongoing (NCT03457818). Interestingly, denosumab was shown to improve hepatic insulin sensitivity in humans[270,271] and, consistently, to reduce fasting plasma glucose in women with diabetes not on antidiabetic medications[272]. Preclinical studies also indicate that denosumab may stimulate human β-cell proliferation[273].

Sclerostin seems to have a central role in the pathogenesis of diabetic bone disease. In mouse models of T1D[273] and T2D[274], administration of anti-sclerostin antibodies seems to reverse the deficits in bone density and micro-fracture healing. No data are currently available on romosozumab, an anti-sclerostin antibody shown to reduce the risk of clinical and vertebral fractures in postmenopausal women with osteoporosis[275].

**CONCLUSION**

Diabetes has a strong impact on bone health, and skeletal fragility is now recognized as a complication of both T1D and T2D. Fracture risk is greater in patients with T1D, and increases with increasing disease duration. Individuals with T1D have decreased BMD, possibly due to absolute insulin deficiency and the inability of exogenous insulin to mirror endogenous insulin secretion. However, the relatively small reduction in BMD does not appear to completely explain the increase in bone fragility observed in T1D[276-296]. On the other hand, individuals with T2D have either normal or increased BMD, which is in contrast with the increased fracture risk observed in this population. Therefore, it is likely that factors that affect bone quality, rather than bone mass, impact the resistance of T2D bones to fracture (Table 2). Increased non-enzymatic glycation of bone matrix proteins, impaired microcirculation and glucotoxicity itself, *i.e.,* the direct detrimental effect of high glucose on bone cells, may all play a role. Reduced bone turnover and increased bone marrow adipogenesis at the expenses of osteogenesis may also contribute. Despite a clear association between T2D and increased fracture risk, evidence supporting an association between prediabetes and fracture risk is inconsistent, and further studies are needed to clarify whether insulin excess has either a beneficial or rather detrimental effect on bone health. The incomplete understanding of the mechanisms underlying diabetic bone disease makes it difficult to develop reliable tools for fracture risk prediction. To date, no single method is deemed optimal for predicting all fracture outcomes in patients with diabetes[32]. Fracture history and risk factors should be assessed in older patients with DM, and measurement of BMD is recommended, if appropriate for the patient’s age and gender[8]. Caution should be used with antidiabetic drugs known to negatively affect bone health, such as TZDs and insulin in patients with T2D. Healthcare professionals involved in the management of T2D patients undergoing bariatric surgery should be aware of the possible detrimental effects on bone health, and implement appropriate nutritional strategies. Due to the lack of randomized clinical trials to evaluate the efficacy of antifracture drugs in diabetes, and observational data indicating similar efficacy in those with or without diabetes, such drugs should be used according to existing indications.

Future studies should focus on the mechanisms underlying diabetic bone disease, and on preventative and treatment strategies to implement in order to reduce the morbidity associated with fractures in this frail population.

**REFERENCES**

1 **Petersen MC**, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev* 2018; **98**: 2133-2223 [PMID: 30067154 DOI: 10.1152/physrev.00063.2017]

2 **Pramojanee SN**, Phimphilai M, Chattipakorn N, Chattipakorn SC. Possible roles of insulin signaling in osteoblasts. *Endocr Res* 2014; **39**: 144-151 [PMID: 24679227 DOI: 10.3109/07435800.2013.879168]

3 **Fulzele K**, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Brüning JC, Clemens TL. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. *Cell* 2010; **142**: 309-319 [PMID: 20655471 DOI: 10.1016/j.cell.2010.06.002]

4 **Thrailkill K**, Bunn RC, Lumpkin C Jr, Wahl E, Cockrell G, Morris L, Kahn CR, Fowlkes J, Nyman JS. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone. *J Diabetes Res* 2014; **2014**: 703589 [PMID: 24963495 DOI: 10.1155/2014/703589]

5 **Zoch ML**, Abou DS, Clemens TL, Thorek DL, Riddle RC. In vivo radiometric analysis of glucose uptake and distribution in mouse bone. *Bone Res* 2016; **4**: 16004 [PMID: 27088042 DOI: 10.1038/boneres.2016.4]

6 **Wu S**, Zhang Y, De Luca F. The effect of a high-calorie diet on bone growth is mediated by the insulin receptor. *Bone* 2019; **122**: 166-175 [PMID: 30798001 DOI: 10.1016/j.bone.2019.02.021]

7 **Fulzele K**, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. *J Biol Chem* 2007; **282**: 25649-25658 [PMID: 17553792 DOI: 10.1074/jbc.M700651200]

8 American Diabetes Association. Standards of Medical Care in Diabetes - 2019. Available at http://care.diabetesjournals.org/content/42/Supplement\_1

9 **Janghorbani M**, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. *Am J Epidemiol* 2007; **166**: 495-505 [PMID: 17575306 DOI: 10.1093/aje/kwm106]

10 **Shah VN**, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. *Diabet Med* 2015; **32**: 1134-1142 [PMID: 26096918 DOI: 10.1111/dme.12734]

11 **Dhaliwal R**, Foster NC, Boyle C, Al Mukaddam M, Weinstock RS, Rickels MR, Shah VN, DiMeglio LA. Determinants of fracture in adults with type 1 diabetes in the USA: Results from the T1D Exchange Clinic Registry. *J Diabetes Complications* 2018; **32**: 1006-1011 [PMID: 30220582 DOI: 10.1016/j.jdiacomp.2018.08.016]

12 **Vestergaard P**, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. *Diabetologia* 2005; **48**: 1292-1299 [PMID: 15909154 DOI: 10.1007/s00125-005-1786-3]

13 **Wang H**, Ba Y, Xing Q, Du JL. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. *BMJ Open* 2019; **9**: e024067 [PMID: 30610024 DOI: 10.1136/bmjopen-2018-024067]

14 **Moayeri A**, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. *Ther Clin Risk Manag* 2017; **13**: 455-468 [PMID: 28442913 DOI: 10.2147/TCRM.S131945]

15 **Holmberg AH**, Johnell O, Nilsson PM, Nilsson J, Berglund G, Akesson K. Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. *Osteoporos Int* 2006; **17**: 1065-1077 [PMID: 16758143 DOI: 10.1007/s00198-006-0137-7]

16 **Patel S**, Hyer S, Tweed K, Kerry S, Allan K, Rodin A, Barron J. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. *Calcif Tissue Int* 2008; **82**: 87-91 [PMID: 18175036 DOI: 10.1007/s00223-007-9082-5]

17 **Wallace C**, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C. Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. *Diabetes Care* 2002; **25**: 1983-1986 [PMID: 12401743 DOI: 10.2337/diacare.25.11.1983]

18 **Maurer MS**, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. *J Gerontol A Biol Sci Med Sci* 2005; **60**: 1157-1162 [PMID: 16183956 DOI: 10.1093/gerona/60.9.1157]

19 **Schwartz AV**, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. *J Clin Endocrinol Metab* 2001; **86**: 32-38 [PMID: 11231974 DOI: 10.1210/jcem.86.1.7139]

20 **Sarodnik C**, Bours SPG, Schaper NC, van den Bergh JP, van Geel TACM. The risks of sarcopenia, falls and fractures in patients with type 2 diabetes mellitus. *Maturitas* 2018; **109**: 70-77 [PMID: 29452785 DOI: 10.1016/j.maturitas.2017.12.011]

21 **Schwartz AV**, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW, Faulkner KA, Harris TB; Health, Aging, and Body Composition Study. Diabetes-related complications, glycemic control, and falls in older adults. *Diabetes Care* 2008; **31**: 391-396 [PMID: 18056893 DOI: 10.2337/dc07-1152]

22 **Kadam PD**, Chuan HH. Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. *Int Urogynecol J* 2016; **27**: 505 [PMID: 26811110 DOI: 10.1007/s00192-016-2952-5]

23 **Shah VN**, Carpenter RD, Ferguson VL, Schwartz AV. Bone health in type 1 diabetes. *Curr Opin Endocrinol Diabetes Obes* 2018; **25**: 231-236 [PMID: 29794498 DOI: 10.1097/MED.0000000000000421]

24 **Yamamoto M**, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. *J Bone Miner Res* 2009; **24**: 702-709 [PMID: 19049338 DOI: 10.1359/jbmr.081207]

25 **Rønne MS**, Heidemann M, Lylloff L, Schou AJ, Tarp J, Bugge A, Laursen JO, Jørgensen NR, Husby S, Wedderkopp N, Mølgaard C. Bone mass development is sensitive to insulin resistance in adolescent boys. *Bone* 2019; **122**: 1-7 [PMID: 30738213 DOI: 10.1016/j.bone.2019.02.005]

26 **Napoli N**, Conte C, Pedone C, Strotmeyer ES, Barbour KE, Black DM, Samelson EJ, Schwartz AV. Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults. *J Clin Endocrinol Metab* 2019; **104**: 3303-3310 [PMID: 30802282 DOI: 10.1210/jc.2018-02539]

27 **Looker AC**, Eberhardt MS, Saydah SH. Diabetes and fracture risk in older U.S. adults. *Bone* 2016; **82**: 9-15 [PMID: 25576672 DOI: 10.1016/j.bone.2014.12.008]

28 **Napoli N**, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TT, Barrett-Connor E, Palermo L, Orwoll ES, Cummings SR, Black DM, Schwartz AV. Fracture risk in diabetic elderly men: the MrOS study. *Diabetologia* 2014; **57**: 2057-2065 [PMID: 24908567 DOI: 10.1007/s00125-014-3289-6]

29 **Holmberg AH**, Nilsson PM, Nilsson JA, Akesson K. The association between hyperglycemia and fracture risk in middle age. A prospective, population-based study of 22,444 men and 10,902 women. *J Clin Endocrinol Metab* 2008; **93**: 815-822 [PMID: 18073298 DOI: 10.1210/jc.2007-0843]

30 **Schwartz AV**, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM; Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. *JAMA* 2011; **305**: 2184-2192 [PMID: 21632482 DOI: 10.1001/jama.2011.715]

31 **Giangregorio LM**, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. FRAX underestimates fracture risk in patients with diabetes. *J Bone Miner Res* 2012; **27**: 301-308 [PMID: 22052532 DOI: 10.1002/jbmr.556]

32 **Leslie WD**, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. *J Bone Miner Res* 2018; **33**: 1923-1930 [PMID: 29953670 DOI: 10.1002/jbmr.3538]

33 **Napoli N**, Strollo R, Paladini A, Briganti SI, Pozzilli P, Epstein S. The alliance of mesenchymal stem cells, bone, and diabetes. *Int J Endocrinol* 2014; **2014**: 690783 [PMID: 25140176 DOI: 10.1155/2014/690783]

34 **Siddiqui JA**, Partridge NC. Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. *Physiology* (Bethesda) 2016; **31**: 233-245 [PMID: 27053737 DOI: 10.1152/physiol.00061.2014]

35 **Fowlkes JL**, Bunn RC, Liu L, Wahl EC, Coleman HN, Cockrell GE, Perrien DS, Lumpkin CK Jr, Thrailkill KM. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. *Endocrinology* 2008; **149**: 1697-1704 [PMID: 18162513 DOI: 10.1210/en.2007-1408]

36 **Lu H**, Kraut D, Gerstenfeld LC, Graves DT. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. *Endocrinology* 2003; **144**: 346-352 [PMID: 12488363 DOI: 10.1210/en.2002-220072]

37 **Botolin S**, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. *Endocrinology* 2005; **146**: 3622-3631 [PMID: 15905321 DOI: 10.1210/en.2004-1677]

38 **Botolin S**, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. *Endocrinology* 2007; **148**: 198-205 [PMID: 17053023 DOI: 10.1210/en.2006-1006]

39 **Hie M**, Iitsuka N, Otsuka T, Tsukamoto I. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. *Int J Mol Med* 2011; **28**: 455-462 [PMID: 21567076 DOI: 10.3892/ijmm.2011.697]

40 **Crane JL**, Zhao L, Frye JS, Xian L, Qiu T, Cao X. IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass. *Bone Res* 2013; **1**: 186-194 [PMID: 26273502 DOI: 10.4248/BR201302007]

41 **Yakar S**, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. *J Clin Invest* 2002; **110**: 771-781 [PMID: 12235108 DOI: 10.1172/JCI15463]

42 **Zhang M**, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. *J Biol Chem* 2002; **277**: 44005-44012 [PMID: 12215457 DOI: 10.1074/jbc.M208265200]

43 **Brenner RE**, Riemenschneider B, Blum W, Mörike M, Teller WM, Pirsig W, Heinze E. Defective stimulation of proliferation and collagen biosynthesis of human bone cells by serum from diabetic patients. *Acta Endocrinol (Copenh)* 1992; **127**: 509-514 [PMID: 1283477]

44 **Hamed EA**, Faddan NH, Elhafeez HA, Sayed D. Parathormone--25(OH)-vitamin D axis and bone status in children and adolescents with type 1 diabetes mellitus. *Pediatr Diabetes* 2011; **12**: 536-546 [PMID: 21426456 DOI: 10.1111/j.1399-5448.2010.00739.x]

45 **Motyl KJ**, McCauley LK, McCabe LR. Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. *J Cell Physiol* 2012; **227**: 1326-1334 [PMID: 21604269 DOI: 10.1002/jcp.22844]

46 **Qiu T**, Crane JL, Xie L, Xian L, Xie H, Cao X. IGF-I induced phosphorylation of PTH receptor enhances osteoblast to osteocyte transition. *Bone Res* 2018; **6**: 5 [PMID: 29507819 DOI: 10.1038/s41413-017-0002-7]

47 **Esposito K**, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* 2002; **106**: 2067-2072 [PMID: 12379575]

48 **Gonzalez Y**, Herrera MT, Soldevila G, Garcia-Garcia L, Fabián G, Pérez-Armendariz EM, Bobadilla K, Guzmán-Beltrán S, Sada E, Torres M. High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes. *BMC Immunol* 2012; **13**: 19 [PMID: 22500980 DOI: 10.1186/1471-2172-13-19]

49 **Assuma R**, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. *J Immunol* 1998; **160**: 403-409 [PMID: 9551997]

50 **Delima AJ**, Karatzas S, Amar S, Graves DT. Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. *J Infect Dis* 2002; **186**: 511-516 [PMID: 12195378 DOI: 10.1086/341778]

51 **Franchimont N**, Wertz S, Malaise M. Interleukin-6: An osteotropic factor influencing bone formation? *Bone* 2005; **37**: 601-606 [PMID: 16112634 DOI: 10.1016/j.bone.2005.06.002]

52 **Gilbert LC**, Chen H, Lu X, Nanes MS. Chronic low dose tumor necrosis factor-α (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts. *Bone* 2013; **56**: 174-183 [PMID: 23756233 DOI: 10.1016/j.bone.2013.06.002]

53 **Perrien DS**, Brown EC, Fletcher TW, Irby DJ, Aronson J, Gao GG, Skinner RA, Hogue WR, Feige U, Suva LJ, Ronis MJ, Badger TM, Lumpkin CK Jr. Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis. *J Pharmacol Exp Ther* 2002; **303**: 904-908 [PMID: 12438508 DOI: 10.1124/jpet.102.039636]

54 **Coe LM**, Irwin R, Lippner D, McCabe LR. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. *J Cell Physiol* 2011; **226**: 477-483 [PMID: 20677222 DOI: 10.1002/jcp.22357]

55 **Gilbert L**, He X, Farmer P, Boden S, Kozlowski M, Rubin J, Nanes MS. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. *Endocrinology* 2000; **141**: 3956-3964 [PMID: 11089525 DOI: 10.1210/endo.141.11.7739]

56 **Boyce BF**, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. *Endocrinology* 1989; **125**: 1142-1150 [PMID: 2788075 DOI: 10.1210/endo-125-3-1142]

57 **Sassi F**, Buondonno I, Luppi C, Spertino E, Stratta E, Di Stefano M, Ravazzoli M, Isaia G, Trento M, Passera P, Porta M, Isaia GC, D'Amelio P. Type 2 diabetes affects bone cells precursors and bone turnover. *BMC Endocr Disord* 2018; **18**: 55 [PMID: 30089481 DOI: 10.1186/s12902-018-0283-x]

58 **Lai X**, Price C, Modla S, Thompson WR, Caplan J, Kirn-Safran CB, Wang L. The dependences of osteocyte network on bone compartment, age, and disease. *Bone Res* 2015; **3** [PMID: 26213632 DOI: 10.1038/boneres.2015.9]

59 **Portal-Núñez S**, Lozano D, de Castro LF, de Gortázar AR, Nogués X, Esbrit P. Alterations of the Wnt/beta-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. *FEBS Lett* 2010; **584**: 3095-3100 [PMID: 20621835 DOI: 10.1016/j.febslet.2010.05.047]

60 **Villarino ME**, Sánchez LM, Bozal CB, Ubios AM. Influence of short-term diabetes on osteocytic lacunae of alveolar bone. A histomorphometric study. *Acta Odontol Latinoam* 2006; **19**: 23-28 [PMID: 17121195]

61 **Sapir-Koren R**, Livshits G. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? *Osteoporos Int* 2014; **25**: 2685-2700 [PMID: 25030653 DOI: 10.1007/s00198-014-2808-0]

62 **Winkler DG**, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. *EMBO J* 2003; **22**: 6267-6276 [PMID: 14633986 DOI: 10.1093/emboj/cdg599]

63 **Sutherland MK**, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. *Bone* 2004; **35**: 828-835 [PMID: 15454089 DOI: 10.1016/j.bone.2004.05.023]

64 **Neumann T**, Hofbauer LC, Rauner M, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G, Hamann C, Sämann A. Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. *Clin Endocrinol (Oxf)* 2014; **80**: 649-655 [PMID: 24237244 DOI: 10.1111/cen.12364]

65 **Daniele G**, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, Tripathy D, Jenkinson C, Folli F. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. *Diabetes Care* 2015; **38**: 1509-1517 [PMID: 26084344 DOI: 10.2337/dc14-2989]

66 **García-Martín A**, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2012; **97**: 234-241 [PMID: 22031520 DOI: 10.1210/jc.2011-2186]

67 **Starup-Linde J**, Lykkeboe S, Gregersen S, Hauge EM, Langdahl BL, Handberg A, Vestergaard P. Bone Structure and Predictors of Fracture in Type 1 and Type 2 Diabetes. *J Clin Endocrinol Metab* 2016; **101**: 928-936 [PMID: 26756117 DOI: 10.1210/jc.2015-3882]

68 **Rubin MR**. Bone cells and bone turnover in diabetes mellitus. *Curr Osteoporos Rep* 2015; **13**: 186-191 [PMID: 25740570 DOI: 10.1007/s11914-015-0265-0]

69 **Hamann C**, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. *J Bone Miner Res* 2013; **28**: 627-638 [PMID: 23109114 DOI: 10.1002/jbmr.1803]

70 **Saag KG**, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. *N Engl J Med* 2017; **377**: 1417-1427 [PMID: 28892457 DOI: 10.1056/NEJMoa1708322]

71 **Mabilleau G**, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. *Diabetologia* 2008; **51**: 1035-1040 [PMID: 18389210 DOI: 10.1007/s00125-008-0992-1]

72 **Loureiro MB**, Ururahy MA, Freire-Neto FP, Oliveira GH, Duarte VM, Luchessi AD, Brandão-Neto J, Hirata RD, Hirata MH, Maciel-Neto JJ, Arrais RF, Almeida MG, Rezende AA. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes. *Diabetes Res Clin Pract* 2014; **103**: 452-457 [PMID: 24529565 DOI: 10.1016/j.diabres.2013.12.018]

73 **Wittrant Y**, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, Abboud-Werner SL. High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. *Bone* 2008; **42**: 1122-1130 [PMID: 18378205 DOI: 10.1016/j.bone.2008.02.006]

74 **Hie M**, Shimono M, Fujii K, Tsukamoto I. Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. *Bone* 2007; **41**: 1045-1050 [PMID: 17916452 DOI: 10.1016/j.bone.2007.08.030]

75 **Thrailkill KM**, Clay Bunn R, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, Uppuganti S, Lumpkin CK Jr, Fowlkes JL. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. *Bone* 2016; **82**: 101-107 [PMID: 26211996 DOI: 10.1016/j.bone.2015.07.025]

76 **Motyl K**, McCabe LR. Streptozotocin, type I diabetes severity and bone. *Biol Proced Online* 2009; **11**: 296-315 [PMID: 19495918 DOI: 10.1007/s12575-009-9000-5]

77 **Roszer T**. Inflammation as death or life signal in diabetic fracture healing. *Inflamm Res* 2011; **60**: 3-10 [PMID: 20845059 DOI: 10.1007/s00011-010-0246-9]

78 **Hu Z**, Ma C, Liang Y, Zou S, Liu X. Osteoclasts in bone regeneration under type 2 diabetes mellitus. *Acta Biomater* 2019; **84**: 402-413 [PMID: 30508657 DOI: 10.1016/j.actbio.2018.11.052]

79 **Hough FS**, Pierroz DD, Cooper C, Ferrari SL; IOF CSA Bone and Diabetes Working Group. MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. *Eur J Endocrinol* 2016; **174**: R127-R138 [PMID: 26537861 DOI: 10.1530/EJE-15-0820]

80 **Farlay D**, Armas LA, Gineyts E, Akhter MP, Recker RR, Boivin G. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. *J Bone Miner Res* 2016; **31**: 190-195 [PMID: 26234180 DOI: 10.1002/jbmr.2607]

81 **Eller-Vainicher C**, Zhukouskaya VV, Tolkachev YV, Koritko SS, Cairoli E, Grossi E, Beck-Peccoz P, Chiodini I, Shepelkevich AP. Low bone mineral density and its predictors in type 1 diabetic patients evaluated by the classic statistics and artificial neural network analysis. *Diabetes Care* 2011; **34**: 2186-2191 [PMID: 21852680 DOI: 10.2337/dc11-0764]

82 **Campos Pastor MM**, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, García-Cervigón AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. *Osteoporos Int* 2000; **11**: 455-459 [PMID: 10912849]

83 **Clausen P**, Feldt-Rasmussen B, Jacobsen P, Rossing K, Parving HH, Nielsen PK, Feldt-Rasmussen U, Olgaard K. Microalbuminuria as an early indicator of osteopenia in male insulin-dependent diabetic patients. *Diabet Med* 1997; **14**: 1038-1043 [PMID: 9455931 DOI: 10.1002/(SICI)1096-9136(199712)14:12<1038::AID-DIA509>3.0.CO;2-1]

84 **Muñoz-Torres M**, Jódar E, Escobar-Jiménez F, López-Ibarra PJ, Luna JD. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. *Calcif Tissue Int* 1996; **58**: 316-319 [PMID: 8661964]

85 **Rozadilla A**, Nolla JM, Montaña E, Fiter J, Gómez-Vaquero C, Soler J, Roig-Escofet D. Bone mineral density in patients with type 1 diabetes mellitus. *Joint Bone Spine* 2000; **67**: 215-218 [PMID: 10875321]

86 **Strotmeyer ES**, Cauley JA, Orchard TJ, Steenkiste AR, Dorman JS. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. *Diabetes Care* 2006; **29**: 306-311 [PMID: 16443878 DOI: 10.2337/diacare.29.02.06.dc05-1353]

87 **Franceschi R**, Longhi S, Cauvin V, Fassio A, Gallo G, Lupi F, Reinstadler P, Fanolla A, Gatti D, Radetti G. Bone Geometry, Quality, and Bone Markers in Children with Type 1 Diabetes Mellitus. *Calcif Tissue Int* 2018; **102**: 657-665 [PMID: 29290007 DOI: 10.1007/s00223-017-0381-1]

88 **Joshi A**, Varthakavi P, Chadha M, Bhagwat N. A study of bone mineral density and its determinants in type 1 diabetes mellitus. *J Osteoporos* 2013; **2013**: 397814 [PMID: 23607045 DOI: 10.1155/2013/397814]

89 **Zhukouskaya VV**, Eller-Vainicher C, Shepelkevich AP, Dydyshko Y, Cairoli E, Chiodini I. Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice. *J Endocrinol Invest* 2015; **38**: 941-950 [PMID: 25863666 DOI: 10.1007/s40618-015-0284-9]

90 **Bonfig W**, Kapellen T, Dost A, Fritsch M, Rohrer T, Wolf J, Holl RW; Diabetes Patienten Verlaufsdokumentationssystem Initiative of the German Working Group for Pediatric Diabetology and the German Bundesministerium für Bildung und Forschung Competence Net for Diabetes Mellitus. Growth in children and adolescents with type 1 diabetes. *J Pediatr* 2012; **160**: 900-3.e2 [PMID: 22244464 DOI: 10.1016/j.jpeds.2011.12.007]

91 **Maddaloni E**, Cavallari I, Napoli N, Conte C. Vitamin D and Diabetes Mellitus. *Front Horm Res* 2018; **50**: 161-176 [PMID: 29597238 DOI: 10.1159/000486083]

92 **Hamilton EJ**, Drinkwater JJ, Chubb SAP, Rakic V, Kamber N, Zhu K, Prince RL, Davis WA, Davis TME. A 10-Year Prospective Study of Bone Mineral Density and Bone Turnover in Males and Females With Type 1 Diabetes. *J Clin Endocrinol Metab* 2018; **103**: 3531-3539 [PMID: 30032248 DOI: 10.1210/jc.2018-00850]

93 **Ma L**, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. *Eur J Epidemiol* 2012; **27**: 319-332 [PMID: 22451239 DOI: 10.1007/s10654-012-9674-x]

94 **Conte C**, Epstein S, Napoli N. Insulin resistance and bone: a biological partnership. *Acta Diabetol* 2018; **55**: 305-314 [PMID: 29333578 DOI: 10.1007/s00592-018-1101-7]

95 **Abrahamsen B**, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. *Diabet Med* 2000; **17**: 124-129 [PMID: 10746482]

96 **Reid IR**, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. *Am J Physiol* 1993; **265**: E655-E659 [PMID: 8238341 DOI: 10.1152/ajpendo.1993.265.4.E655]

97 **Stolk RP**, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhäger JC, Lamberts SW, Grobbee DE. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. *Bone* 1996; **18**: 545-549 [PMID: 8805995]

98 **Dennison EM**, Syddall HE, Aihie Sayer A, Craighead S, Phillips DI, Cooper C. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? *Diabetologia* 2004; **47**: 1963-1968 [PMID: 15565368 DOI: 10.1007/s00125-004-1560-y]

99 **Haffner SM**, Bauer RL. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. *Metabolism* 1993; **42**: 735-738 [PMID: 8510518]

100 **Kim SM**, Cui J, Rhyu J, Guo X, Chen YI, Hsueh WA, Rotter JI, Goodarzi MO. Association between site-specific bone mineral density and glucose homeostasis and anthropometric traits in healthy men and women. *Clin Endocrinol (Oxf)* 2018; **88**: 848-855 [PMID: 29575061 DOI: 10.1111/cen.13602]

101 **Srikanthan P**, Crandall CJ, Miller-Martinez D, Seeman TE, Greendale GA, Binkley N, Karlamangla AS. Insulin resistance and bone strength: findings from the study of midlife in the United States. *J Bone Miner Res* 2014; **29**: 796-803 [PMID: 23983216 DOI: 10.1002/jbmr.2083]

102 **Michel BA**, Bloch DA, Fries JF. Weight-bearing exercise, overexercise, and lumbar bone density over age 50 years. *Arch Intern Med* 1989; **149**: 2325-2329 [PMID: 2802897]

103 **Albala C**, Yáñez M, Devoto E, Sostin C, Zeballos L, Santos JL. Obesity as a protective factor for postmenopausal osteoporosis. *Int J Obes Relat Metab Disord* 1996; **20**: 1027-1032 [PMID: 8923160]

104 **Goulding A**, Taylor RW. Plasma leptin values in relation to bone mass and density and to dynamic biochemical markers of bone resorption and formation in postmenopausal women. *Calcif Tissue Int* 1998; **63**: 456-458 [PMID: 9817937]

105 **Ishii S**, Cauley JA, Greendale GA, Nielsen C, Karvonen-Gutierrez C, Ruppert K, Karlamangla AS. Pleiotropic effects of obesity on fracture risk: the Study of Women's Health Across the Nation. *J Bone Miner Res* 2014; **29**: 2561-2570 [PMID: 24986773 DOI: 10.1002/jbmr.2303]

106 **Cummings SR**, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. *N Engl J Med* 1995; **332**: 767-773 [PMID: 7862179 DOI: 10.1056/NEJM199503233321202]

107 **DiPietro L**, Welch GA, Davis DR, Drane JW, Macera CA. Body mass and risk of hip fracture among a national cohort of postmenopausal white women: a reanalysis. *Obes Res* 1993; **1**: 357-363 [PMID: 16350586]

108 **Joakimsen RM**, Fønnebø V, Magnus JH, Tollan A, Søgaard AJ. The Tromsø Study: body height, body mass index and fractures. *Osteoporos Int* 1998; **8**: 436-442 [PMID: 9850351]

109 **Paganini-Hill A**, Chao A, Ross RK, Henderson BE. Exercise and other factors in the prevention of hip fracture: the Leisure World study. *Epidemiology* 1991; **2**: 16-25 [PMID: 2021661]

110 **Compston JE**, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, Díez-Pérez A, Lindsay R, Saag KG, Netelenbos JC, Gehlbach S, Hooven FH, Flahive J, Adachi JD, Rossini M, Lacroix AZ, Roux C, Sambrook PN, Siris ES; Glow Investigators. Obesity is not protective against fracture in postmenopausal women: GLOW. *Am J Med* 2011; **124**: 1043-1050 [PMID: 22017783 DOI: 10.1016/j.amjmed.2011.06.013]

111 **Johansson H**, Kanis JA, Odén A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez A, Eisman JA, Fujiwara S, Glüer CC, Goltzman D, Hans D, Khaw KT, Krieg MA, Kröger H, LaCroix AZ, Lau E, Leslie WD, Mellström D, Melton LJ 3rd, O'Neill TW, Pasco JA, Prior JC, Reid DM, Rivadeneira F, van Staa T, Yoshimura N, Zillikens MC. A meta-analysis of the association of fracture risk and body mass index in women. *J Bone Miner Res* 2014; **29**: 223-233 [PMID: 23775829 DOI: 10.1002/jbmr.2017]

112 **Premaor MO**, Ensrud K, Lui L, Parker RA, Cauley J, Hillier TA, Cummings S, Compston JE; Study of Osteoporotic Fractures. Risk factors for nonvertebral fracture in obese older women. *J Clin Endocrinol Metab* 2011; **96**: 2414-2421 [PMID: 21677038 DOI: 10.1210/jc.2011-0076]

113 **Prieto-Alhambra D**, Premaor MO, Fina Avilés F, Hermosilla E, Martinez-Laguna D, Carbonell-Abella C, Nogués X, Compston JE, Díez-Pérez A. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. *J Bone Miner Res* 2012; **27**: 294-300 [PMID: 22095911 DOI: 10.1002/jbmr.1466]

114 **Watts NB**; GLOW investigators. Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW). *Nat Rev Endocrinol* 2014; **10**: 412-422 [PMID: 24751880 DOI: 10.1038/nrendo.2014.55]

115 **Savvidis C**, Tournis S, Dede AD. Obesity and bone metabolism. *Hormones (Athens)* 2018; **17**: 205-217 [PMID: 29858847 DOI: 10.1007/s42000-018-0018-4]

116 **Søgaard AJ**, Holvik K, Omsland TK, Tell GS, Dahl C, Schei B, Falch JA, Eisman JA, Meyer HE. Abdominal obesity increases the risk of hip fracture. A population-based study of 43,000 women and men aged 60-79 years followed for 8 years. Cohort of Norway. *J Intern Med* 2015; **277**: 306-317 [PMID: 24597977 DOI: 10.1111/joim.12230]

117 **Zhang J**, Jin Y, Xu S, Zheng J, Zhang Q, Chen J, Huang Y, Shao H, Yang D, Ying Q. Associations of fat mass and fat distribution with bone mineral density in Chinese obese population. *J Clin Densitom* 2015; **18**: 44-49 [PMID: 24815308 DOI: 10.1016/j.jocd.2014.03.001]

118 **Hind K**, Pearce M, Birrell F. Total and Visceral Adiposity Are Associated With Prevalent Vertebral Fracture in Women but Not Men at Age 62 Years: The Newcastle Thousand Families Study. *J Bone Miner Res* 2017; **32**: 1109-1115 [PMID: 28261864 DOI: 10.1002/jbmr.3085]

119 **Machado LG**, Domiciano DS, Figueiredo CP, Caparbo VF, Takayama L, Oliveira RM, Lopes JB, Menezes PR, Pereira RM. Visceral fat measured by DXA is associated with increased risk of non-spine fractures in nonobese elderly women: a population-based prospective cohort analysis from the São Paulo Ageing &amp; Health (SPAH) Study. *Osteoporos Int* 2016; **27**: 3525-3533 [PMID: 27351667 DOI: 10.1007/s00198-016-3682-8]

120 **Ibrahim MM**. Subcutaneous and visceral adipose tissue: structural and functional differences. *Obes Rev* 2010; **11**: 11-18 [PMID: 19656312 DOI: 10.1111/j.1467-789X.2009.00623.x]

121 **Ritchie SA**, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. *Nutr Metab Cardiovasc Dis* 2007; **17**: 319-326 [PMID: 17110092 DOI: 10.1016/j.numecd.2006.07.005]

122 **Lee JH**, Lee YH, Jung KH, Kim MK, Jang HW, Kim TK, Kim HJ, Jo YS, Shong M, Lee TY, Ku BJ. Bone mineral density in prediabetic men. *Korean Diabetes J* 2010; **34**: 294-302 [PMID: 21076577 DOI: 10.4093/kdj.2010.34.5.294]

123 **Pollock NK**, Bernard PJ, Wenger K, Misra S, Gower BA, Allison JD, Zhu H, Davis CL. Lower bone mass in prepubertal overweight children with prediabetes. *J Bone Miner Res* 2010; **25**: 2760-2769 [PMID: 20641032 DOI: 10.1002/jbmr.184]

124 **Pater A**, Sypniewska G, Pilecki O. Biochemical markers of bone cell activity in children with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab* 2010; **23**: 81-86 [PMID: 20432810]

125 **Starup-Linde J**. Diabetes, biochemical markers of bone turnover, diabetes control, and bone. *Front Endocrinol (Lausanne)* 2013; **4**: 21 [PMID: 23482417 DOI: 10.3389/fendo.2013.00021]

126 **Starup-Linde J**, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers. *Osteoporos Int* 2014; **25**: 1697-1708 [PMID: 24676844 DOI: 10.1007/s00198-014-2676-7]

127 **Hygum K**, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. *Eur J Endocrinol* 2017; **176**: R137-R157 [PMID: 28049653 DOI: 10.1530/EJE-16-0652]

128 **Mitchell A**, Fall T, Melhus H, Wolk A, Michaëlsson K, Byberg L. Type 2 Diabetes in Relation to Hip Bone Density, Area, and Bone Turnover in Swedish Men and Women: A Cross-Sectional Study. *Calcif Tissue Int* 2018; **103**: 501-511 [PMID: 29946974 DOI: 10.1007/s00223-018-0446-9]

129 **Purnamasari D**, Puspitasari MD, Setiyohadi B, Nugroho P, Isbagio H. Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study. *BMC Endocr Disord* 2017; **17**: 72 [PMID: 29187183 DOI: 10.1186/s12902-017-0224-0]

130 **Starup-Linde J**, Lykkeboe S, Gregersen S, Hauge EM, Langdahl BL, Handberg A, Vestergaard P. Differences in biochemical bone markers by diabetes type and the impact of glucose. *Bone* 2016; **83**: 149-155 [PMID: 26555635 DOI: 10.1016/j.bone.2015.11.004]

131 **Krakauer JC**, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. *Diabetes* 1995; **44**: 775-782 [PMID: 7789645 DOI: 10.2337/diab.44.7.775]

132 **Manavalan JS**, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, Kousteni S, Rubin MR. Circulating osteogenic precursor cells in type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2012; **97**: 3240-3250 [PMID: 22740707 DOI: 10.1210/jc.2012-1546]

133 **Dobnig H**, Piswanger-Sölkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. *J Clin Endocrinol Metab* 2006; **91**: 3355-3363 [PMID: 16735485 DOI: 10.1210/jc.2006-0460]

134 **Yamamoto M**, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. *J Clin Endocrinol Metab* 2012; **97**: 1277-1284 [PMID: 22337915 DOI: 10.1210/jc.2011-2537]

135 **Napoli N**, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL; IOF Bone and Diabetes Working Group. Mechanisms of diabetes mellitus-induced bone fragility. *Nat Rev Endocrinol* 2017; **13**: 208-219 [PMID: 27658727 DOI: 10.1038/nrendo.2016.153]

136 **Holloway-Kew KL**, De Abreu LLF, Kotowicz MA, Sajjad MA, Pasco JA. Bone Turnover Markers in Men and Women with Impaired Fasting Glucose and Diabetes. *Calcif Tissue Int* 2019; **104**: 599-604 [PMID: 30680432 DOI: 10.1007/s00223-019-00527-y]

137 **Jiajue R**, Jiang Y, Wang O, Li M, Xing X, Cui L, Yin J, Xu L, Xia W. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus. *Osteoporos Int* 2014; **25**: 1999-2005 [PMID: 24760246 DOI: 10.1007/s00198-014-2714-5]

138 **Scheller EL**, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY, Bredella MA, Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. *Nat Commun* 2015; **6**: 7808 [PMID: 26245716 DOI: 10.1038/ncomms8808]

139 **Botolin S**, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. *J Cell Biochem* 2006; **99**: 411-424 [PMID: 16619259 DOI: 10.1002/jcb.20842]

140 **Kim TY**, Schafer AL. Diabetes and Bone Marrow Adiposity. *Curr Osteoporos Rep* 2016; **14**: 337-344 [PMID: 27714580 DOI: 10.1007/s11914-016-0336-x]

141 **Devlin MJ**, Rosen CJ. The bone-fat interface: basic and clinical implications of marrow adiposity. *Lancet Diabetes Endocrinol* 2015; **3**: 141-147 [PMID: 24731667 DOI: 10.1016/S2213-8587(14)70007-5]

142 **Motyl KJ**, Raetz M, Tekalur SA, Schwartz RC, McCabe LR. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption. *Am J Physiol Regul Integr Comp Physiol* 2011; **300**: R1250-R1260 [PMID: 21346244 DOI: 10.1152/ajpregu.00764.2010]

143 **Armas LA**, Akhter MP, Drincic A, Recker RR. Trabecular bone histomorphometry in humans with Type 1 Diabetes Mellitus. *Bone* 2012; **50**: 91-96 [PMID: 22001578 DOI: 10.1016/j.bone.2011.09.055]

144 **Carvalho AL**, Massaro B, Silva LTPE, Salmon CEG, Fukada SY, Nogueira-Barbosa MH, Elias J Jr, Freitas MCF, Couri CEB, Oliveira MC, Simões BP, Rosen CJ, de Paula FJA. Emerging Aspects of the Body Composition, Bone Marrow Adipose Tissue and Skeletal Phenotypes in Type 1 Diabetes Mellitus. *J Clin Densitom* 2018 [PMID: 30100221 DOI: 10.1016/j.jocd.2018.06.007]

145 **Abdalrahaman N**, McComb C, Foster JE, Lindsay RS, Drummond R, McKay GA, Perry CG, Ahmed SF. The relationship between adiposity, bone density and microarchitecture is maintained in young women irrespective of diabetes status. *Clin Endocrinol* (Oxf) 2017; **87**: 327-335 [PMID: 28656591 DOI: 10.1111/cen.13410]

146 **Sheu Y**, Amati F, Schwartz AV, Danielson ME, Li X, Boudreau R, Cauley JA; Osteoporotic Fractures in Men (MrOS) Research Group. Vertebral bone marrow fat, bone mineral density and diabetes: The Osteoporotic Fractures in Men (MrOS) study. *Bone* 2017; **97**: 299-305 [PMID: 28179169 DOI: 10.1016/j.bone.2017.02.001]

147 **Patsch JM**, Li X, Baum T, Yap SP, Karampinos DC, Schwartz AV, Link TM. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. *J Bone Miner Res* 2013; **28**: 1721-1728 [PMID: 23558967 DOI: 10.1002/jbmr.1950]

148 **Baum T**, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, Masharani UB, Schwartz AV, Li X, Link TM. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? *J Magn Reson Imaging* 2012; **35**: 117-124 [PMID: 22190287 DOI: 10.1002/jmri.22757]

149 **Bredella MA**, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A, Miller KK. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. *Obesity* (Silver Spring) 2011; **19**: 49-53 [PMID: 20467419 DOI: 10.1038/oby.2010.106]

150 **Bani Hassan E**, Demontiero O, Vogrin S, Ng A, Duque G. Marrow Adipose Tissue in Older Men: Association with Visceral and Subcutaneous Fat, Bone Volume, Metabolism, and Inflammation. *Calcif Tissue Int* 2018; **103**: 164-174 [PMID: 29582133 DOI: 10.1007/s00223-018-0412-6]

151 **de Paula FJ**, de Araújo IM, Carvalho AL, Elias J Jr, Salmon CE, Nogueira-Barbosa MH. The Relationship of Fat Distribution and Insulin Resistance with Lumbar Spine Bone Mass in Women. *PLoS One* 2015; **10**: e0129764 [PMID: 26067489 DOI: 10.1371/journal.pone.0129764]

152 **Chaudhuri J**, Bains Y, Guha S, Kahn A, Hall D, Bose N, Gugliucci A, Kapahi P. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. *Cell Metab* 2018; **28**: 337-352 [PMID: 30184484 DOI: 10.1016/j.cmet.2018.08.014]

153 **Alikhani M**, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. *Bone* 2007; **40**: 345-353 [PMID: 17064973 DOI: 10.1016/j.bone.2006.09.011]

154 **Takagi M**, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. *J Bone Miner Res* 1997; **12**: 439-446 [PMID: 9076587 DOI: 10.1359/jbmr.1997.12.3.439]

155 **Chen H**, Liu W, Wu X, Gou M, Shen J, Wang H. Advanced glycation end products induced IL-6 and VEGF-A production and apoptosis in osteocyte-like MLO-Y4 cells by activating RAGE and ERK1/2, P38 and STAT3 signalling pathways. *Int Immunopharmacol* 2017; **52**: 143-149 [PMID: 28910744 DOI: 10.1016/j.intimp.2017.09.004]

156 **Saito M**, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. *Osteoporos Int* 2006; **17**: 1514-1523 [PMID: 16770520 DOI: 10.1007/s00198-006-0155-5]

157 **Neumann T**, Lodes S, Kästner B, Franke S, Kiehntopf M, Lehmann T, Müller UA, Wolf G, Sämann A. High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control. *Osteoporos Int* 2014; **25**: 1527-1533 [PMID: 24599273 DOI: 10.1007/s00198-014-2631-7]

158 **Barzilay JI**, Bůžková P, Zieman SJ, Kizer JR, Djoussé L, Ix JH, Tracy RP, Siscovick DS, Cauley JA, Mukamal KJ. Circulating levels of carboxy‐methyl‐lysine (CML) are associated with hip fracture risk: the Cardiovascular Health Study. *J Bone Miner Res* 2014; **29**: 1061-1066 [PMID: 24877243]

159 **Rubin MR**, Paschalis EP, Poundarik A, Sroga GE, McMahon DJ, Gamsjaeger S, Klaushofer K, Vashishth D. Advanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice. *PLoS One* 2016; **11**: e0154700 [PMID: 27140650 DOI: 10.1371/journal.pone.0154700]

160 **Furst JR**, Bandeira LC, Fan WW, Agarwal S, Nishiyama KK, McMahon DJ, Dworakowski E, Jiang H, Silverberg SJ, Rubin MR. Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. *J Clin Endocrinol Metab* 2016; **101**: 2502-2510 [PMID: 27115060 DOI: 10.1210/jc.2016-1437]

161 **Schwartz AV**, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC; Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes. *J Clin Endocrinol Metab* 2009; **94**: 2380-2386 [PMID: 19383780 DOI: 10.1210/jc.2008-2498]

162 **Yamamoto M**, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. *J Clin Endocrinol Metab* 2008; **93**: 1013-1019 [PMID: 18160470 DOI: 10.1210/jc.2007-1270]

163 **Compston J**. Type 2 diabetes mellitus and bone. *J Intern Med* 2018; **283**: 140-153 [PMID: 29265670 DOI: 10.1111/joim.12725]

164 **Keenan HA**, Maddaloni E. Bone Microarchitecture in Type 1 Diabetes: It Is Complicated. *Curr Osteoporos Rep* 2016; **14**: 351-358 [PMID: 27704394 DOI: 10.1007/s11914-016-0338-8]

165 **Shah VN**, Sippl R, Joshee P, Pyle L, Kohrt WM, Schauer IE, Snell-Bergeon JK. Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. *Osteoporos Int* 2018; **29**: 733-739 [PMID: 29290026 DOI: 10.1007/s00198-017-4353-0]

166 **Shanbhogue VV**, Hansen S, Frost M, Jørgensen NR, Hermann AP, Henriksen JE, Brixen K. Bone Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR-pQCT in Adult Patients With Type 1 Diabetes Mellitus. *J Bone Miner Res* 2015; **30**: 2188-2199 [PMID: 26096924 DOI: 10.1002/jbmr.2573]

167 **Abdalrahaman N**, McComb C, Foster JE, McLean J, Lindsay RS, McClure J, McMillan M, Drummond R, Gordon D, McKay GA, Shaikh MG, Perry CG, Ahmed SF. Deficits in Trabecular Bone Microarchitecture in Young Women With Type 1 Diabetes Mellitus. *J Bone Miner Res* 2015; **30**: 1386-1393 [PMID: 25627460 DOI: 10.1002/jbmr.2465]

168 **Burghardt AJ**, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, Link TM. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2010; **95**: 5045-5055 [PMID: 20719835 DOI: 10.1210/jc.2010-0226]

169 **Patsch JM**, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. *J Bone Miner Res* 2013; **28**: 313-324 [PMID: 22991256 DOI: 10.1002/jbmr.1763]

170 **Pritchard JM**, Giangregorio LM, Atkinson SA, Beattie KA, Inglis D, Ioannidis G, Punthakee Z, Adachi JD, Papaioannou A. Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. *Arthritis Care Res* (Hoboken) 2012; **64**: 83-91 [PMID: 22213724 DOI: 10.1002/acr.20602]

171 **Rubin MR**. Skeletal fragility in diabetes. *Ann N Y Acad Sci* 2017; **1402**: 18-30 [PMID: 28926113 DOI: 10.1111/nyas.13463]

172 **Yang J**, Hong N, Shim JS, Rhee Y, Kim HC. Association of Insulin Resistance with Lower Bone Volume and Strength Index of the Proximal Femur in Nondiabetic Postmenopausal Women. *J Bone Metab* 2018; **25**: 123-132 [PMID: 29900162 DOI: 10.11005/jbm.2018.25.2.123]

173 **Kindler JM**, Pollock NK, Ross HL, Modlesky CM, Singh H, Laing EM, Lewis RD. Obese Versus Normal-Weight Late-Adolescent Females have Inferior Trabecular Bone Microarchitecture: A Pilot Case-Control Study. *Calcif Tissue Int* 2017; **101**: 479-488 [PMID: 28710506 DOI: 10.1007/s00223-017-0303-2]

174 **Kim JH**, Choi HJ, Ku EJ, Hong AR, Kim KM, Kim SW, Cho NH, Shin CS. Regional body fat depots differently affect bone microarchitecture in postmenopausal Korean women. *Osteoporos Int* 2016; **27**: 1161-1168 [PMID: 26475286 DOI: 10.1007/s00198-015-3329-1]

175 **Looker AC**, Sarafrazi Isfahani N, Fan B, Shepherd JA. Trabecular bone scores and lumbar spine bone mineral density of US adults: comparison of relationships with demographic and body size variables. *Osteoporos Int* 2016; **27**: 2467-2475 [PMID: 26952009 DOI: 10.1007/s00198-016-3550-6]

176 **Gilsanz V**, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. *J Clin Endocrinol Metab* 2009; **94**: 3387-3393 [PMID: 19531595 DOI: 10.1210/jc.2008-2422]

177 **Liu CT**, Broe KE, Zhou Y, Boyd SK, Cupples LA, Hannan MT, Lim E, McLean RR, Samelson EJ, Bouxsein ML, Kiel DP. Visceral Adipose Tissue Is Associated With Bone Microarchitecture in the Framingham Osteoporosis Study. *J Bone Miner Res* 2017; **32**: 143-150 [PMID: 27487454 DOI: 10.1002/jbmr.2931]

178 **Verroken C**, Zmierczak HG, Goemaere S, Kaufman JM, Lapauw B. Insulin Resistance Is Associated With Smaller Cortical Bone Size in Nondiabetic Men at the Age of Peak Bone Mass. *J Clin Endocrinol Metab* 2017; **102**: 1807-1815 [PMID: 28001453 DOI: 10.1210/jc.2016-3609]

179 **Burkhardt R**, Moser W, Bartl R, Mahl G. Is diabetic osteoporosis due to microangiopathy? *Lancet* 1981; **1**: 844 [PMID: 6111708]

180 **Xie H**, Cui Z, Wang L, Xia Z, Hu Y, Xian L, Li C, Xie L, Crane J, Wan M, Zhen G, Bian Q, Yu B, Chang W, Qiu T, Pickarski M, Duong LT, Windle JJ, Luo X, Liao E, Cao X. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. *Nat Med* 2014; **20**: 1270-1278 [PMID: 25282358 DOI: 10.1038/nm.3668]

181 **Shanbhogue VV**, Hansen S, Frost M, Jørgensen NR, Hermann AP, Henriksen JE, Brixen K. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. *Eur J Endocrinol* 2016; **174**: 115-124 [PMID: 26537860 DOI: 10.1530/EJE-15-0860]

182 **Irwin R**, LaPres JJ, Kinser S, McCabe LR. Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype. *J Cell Biochem* 2007; **100**: 762-772 [PMID: 17031858 DOI: 10.1002/jcb.21083]

183 **Davies MJ**, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018; **41**: 2669-2701 [PMID: 30291106 DOI: 10.2337/dci18-0033]

184 **Rena G**, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia* 2017; **60**: 1577-1585 [PMID: 28776086 DOI: 10.1007/s00125-017-4342-z]

185 **Chen SC**, Brooks R, Houskeeper J, Bremner SK, Dunlop J, Viollet B, Logan PJ, Salt IP, Ahmed SF, Yarwood SJ. Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms. *Mol Cell Endocrinol* 2017; **440**: 57-68 [PMID: 27856330 DOI: 10.1016/j.mce.2016.11.011]

186 **Cortizo AM**, Sedlinsky C, McCarthy AD, Blanco A, Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. *Eur J Pharmacol* 2006; **536**: 38-46 [PMID: 16564524 DOI: 10.1016/j.ejphar.2006.02.030]

187 **Smieszek A**, Tomaszewski KA, Kornicka K, Marycz K. Metformin Promotes Osteogenic Differentiation of Adipose-Derived Stromal Cells and Exerts Pro-Osteogenic Effect Stimulating Bone Regeneration. *J Clin Med* 2018; **7** [PMID: 30486321 DOI: 10.3390/jcm7120482]

188 **Molinuevo MS**, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. *J Bone Miner Res* 2010; **25**: 211-221 [PMID: 19594306 DOI: 10.1359/jbmr.090732]

189 **Majumdar SR**, Josse RG, Lin M, Eurich DT. Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study. *J Clin Endocrinol Metab* 2016; **101**: 1963-1969 [PMID: 26930183 DOI: 10.1210/jc.2015-4180]

190 **Starup-Linde J**, Gregersen S, Frost M, Vestergaard P. Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes. *Bone* 2017; **95**: 136-142 [PMID: 27890548 DOI: 10.1016/j.bone.2016.11.026]

191 **Starup-Linde J**, Gregersen S, Vestergaard P. Associations with fracture in patients with diabetes: a nested case-control study. *BMJ Open* 2016; **6**: e009686 [PMID: 26873048 DOI: 10.1136/bmjopen-2015-009686]

192 **Pozo L**, Bello F, Suarez A, Ochoa-Martinez FE, Mendez Y, Chang CH, Surani S. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. *World J Diabetes* 2019; **10**: 291-303 [PMID: 31139316 DOI: 10.4239/wjd.v10.i5.291]

193 **Meng J**, Ma X, Wang N, Jia M, Bi L, Wang Y, Li M, Zhang H, Xue X, Hou Z, Zhou Y, Yu Z, He G, Luo X. Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin. *Stem Cell Reports* 2016; **6**: 579-591 [PMID: 26947974 DOI: 10.1016/j.stemcr.2016.02.002]

194 **Wu X**, Li S, Xue P, Li Y. Liraglutide Inhibits the Apoptosis of MC3T3-E1 Cells Induced by Serum Deprivation through cAMP/PKA/β-Catenin and PI3K/AKT/GSK3β Signaling Pathways. *Mol Cells* 2018; **41**: 234-243 [PMID: 29463067 DOI: 10.14348/molcells.2018.2340]

195 **Ma X**, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. *J Bone Miner Res* 2013; **28**: 1641-1652 [PMID: 23427056 DOI: 10.1002/jbmr.1898]

196 **Mansur SA**, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N, Mabilleau G. Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus. *J Cell Physiol* 2015; **230**: 3009-3018 [PMID: 26016732 DOI: 10.1002/jcp.25033]

197 **Driessen JH**, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JP, Vestergaard P, Henry RM. The use of incretins and fractures - a meta-analysis on population-based real life data. *Br J Clin Pharmacol* 2017; **83**: 923-926 [PMID: 27780288 DOI: 10.1111/bcp.13167]

198 **Driessen JH**, van Onzenoort HA, Starup-Linde J, Henry R, Burden AM, Neef C, van den Bergh JP, Vestergaard P, de Vries F. Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs. *Calcif Tissue Int* 2015; **97**: 506-515 [PMID: 26184119 DOI: 10.1007/s00223-015-0037-y]

199 **Mabilleau G**, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. *J Diabetes* 2014; **6**: 260-266 [PMID: 24164867 DOI: 10.1111/1753-0407.12102]

200 **Su B**, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. *Endocrine* 2015; **48**: 107-115 [PMID: 25074632 DOI: 10.1007/s12020-014-0361-4]

201 **Conte C**, Cecere A, Guglielmi G, Napoli N. Letter to the Editor: "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women" by Iepsen E.W., et al. *J Clin Endocrinol Metab* 2015; **100**: L92-L93 [PMID: 26439158 DOI: 10.1210/jc.2015-2970]

202 **Iepsen EW**, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jørgensen NR, Jensen JE, Holst JJ, Madsbad S, Torekov SS. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. *J Clin Endocrinol Metab* 2015; **100**: 2909-2917 [PMID: 26043228 DOI: 10.1210/jc.2015-1176]

203 **Deacon CF**. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. *Diabetes Obes Metab* 2018; **20 Suppl 1**: 34-46 [PMID: 29364584 DOI: 10.1111/dom.13135]

204 **Glorie L**, Behets GJ, Baerts L, De Meester I, D'Haese PC, Verhulst A. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. *Am J Physiol Endocrinol Metab* 2014; **307**: E447-E455 [PMID: 25053403 DOI: 10.1152/ajpendo.00217.2014]

205 **Wang C**, Xiao F, Qu X, Zhai Z, Hu G, Chen X, Zhang X. Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis<i>In Vivo</i> and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption <i>In Vitro</i>. *Front Pharmacol* 2017; **8**: 407 [PMID: 28713268 DOI: 10.3389/fphar.2017.00407]

206 **Driessen JH**, van Onzenoort HA, Starup-Linde J, Henry R, Neef C, van den Bergh J, Vestergaard P, de Vries F, Burden AM. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs. *Pharmacoepidemiol Drug Saf* 2015; **24**: 1017-1025 [PMID: 26183226 DOI: 10.1002/pds.3837]

207 **Driessen JH**, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. *Diabetes Obes Metab* 2017; **19**: 421-428 [PMID: 27943565 DOI: 10.1111/dom.12843]

208 **Dombrowski S**, Kostev K, Jacob L. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. *Osteoporos Int* 2017; **28**: 2421-2428 [PMID: 28455750 DOI: 10.1007/s00198-017-4051-y]

209 **Hou WH**, Chang KC, Li CY, Ou HT. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study. *Br J Clin Pharmacol* 2018; **84**: 2029-2039 [PMID: 29766544 DOI: 10.1111/bcp.13636]

210 **Yang J**, Huang C, Wu S, Xu Y, Cai T, Chai S, Yang Z, Sun F, Zhan S. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials. *PLoS One* 2017; **12**: e0187537 [PMID: 29206832 DOI: 10.1371/journal.pone.0187537]

211 **Ghezzi C**, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. *Diabetologia* 2018; **61**: 2087-2097 [PMID: 30132032 DOI: 10.1007/s00125-018-4656-5]

212 **Blau JE**, Taylor SI. Adverse effects of SGLT2 inhibitors on bone health. *Nat Rev Nephrol* 2018; **14**: 473-474 [PMID: 29875481 DOI: 10.1038/s41581-018-0028-0]

213 U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Revises Label of Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and New Information on Decreased Bone Mineral Density. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm461449.htm. 2016.

214 **Lupsa BC**, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. *Diabetologia* 2018; **61**: 2118-2125 [PMID: 30132031 DOI: 10.1007/s00125-018-4663-6]

215 **Fralick M**, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. *Ann Intern Med* 2019 [PMID: 30597484 DOI: 10.7326/M18-0567]

216 **Ruanpeng D**, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. *Diabetes Metab Res Rev* 2017; **33**: [PMID: 28440590 DOI: 10.1002/dmrr.2903]

217 **Azharuddin M**, Adil M, Ghosh P, Sharma M. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract* 2018; **146**: 180-190 [PMID: 30389620 DOI: 10.1016/j.diabres.2018.10.019]

218 **Donnan JR**, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. *BMJ Open* 2019; **9**: e022577 [PMID: 30813108 DOI: 10.1136/bmjopen-2018-022577]

219 **Li X**, Li T, Cheng Y, Lu Y, Xue M, Xu L, Liu X, Yu X, Sun B, Chen L. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis. *Diabetes Metab Res Rev* 2019; e3170 [PMID: 30983141 DOI: 10.1002/dmrr.3170]

220 **Thulé PM**, Umpierrez G. Sulfonylureas: a new look at old therapy. *Curr Diab Rep* 2014; **14**: 473 [PMID: 24563333 DOI: 10.1007/s11892-014-0473-5]

221 **Wang LC**, Fang FS, Gong YP, Yang G, Li CL. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. *Medicine (Baltimore)* 2018; **97**: e12476 [PMID: 30235745 DOI: 10.1097/MD.0000000000012476]

222 **Schwartz AV**. Diabetes, bone and glucose-lowering agents: clinical outcomes. *Diabetologia* 2017; **60**: 1170-1179 [PMID: 28451714 DOI: 10.1007/s00125-017-4283-6]

223 **Colhoun HM**, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, Reed C, Donnan PT, Guthrie B, Leese GP, McKnight J, Pearson DW, Pearson E, Petrie JR, Philip S, Sattar N, Sullivan FM, McKeigue P; Scottish Diabetes Research Network Epidemiology Group. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. *Diabetologia* 2012; **55**: 2929-2937 [PMID: 22945303 DOI: 10.1007/s00125-012-2668-0]

224 **Rajpathak SN**, Fu C, Brodovicz KG, Engel SS, Lapane K. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. *Drugs Aging* 2015; **32**: 321-327 [PMID: 25825122 DOI: 10.1007/s40266-015-0254-0]

225 **Chen HH**, Horng MH, Yeh SY, Lin IC, Yeh CJ, Muo CH, Sung FC, Kao CH. Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients. *PLoS One* 2015; **10**: e0135530 [PMID: 26317995 DOI: 10.1371/journal.pone.0135530]

226 **Natali A**, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. *Diabetologia* 2006; **49**: 434-441 [PMID: 16477438 DOI: 10.1007/s00125-006-0141-7]

227 **Ahmadian M**, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARγ signaling and metabolism: the good, the bad and the future. *Nat Med* 2013; **19**: 557-566 [PMID: 23652116 DOI: 10.1038/nm.3159]

228 **Viscoli CM**, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN; IRIS Trial Investigators. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. *J Clin Endocrinol Metab* 2017; **102**: 914-922 [PMID: 27935736 DOI: 10.1210/jc.2016-3237]

229 **Zhu ZN**, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. *Bone* 2014; **68**: 115-123 [PMID: 25173606 DOI: 10.1016/j.bone.2014.08.010]

230 **Leanza G**, Maddaloni E, Pitocco D, Conte C, Palermo A, Maurizi AR, Pantano AL, Suraci C, Altomare M, Strollo R, Manfrini S, Pozzilli P, Schwartz AV, Napoli N. Risk factors for fragility fractures in type 1 diabetes. *Bone* 2019; **125**: 194-199 [PMID: 31059862 DOI: 10.1016/j.bone.2019.04.017]

231 **Losada-Grande E**, Hawley S, Soldevila B, Martinez-Laguna D, Nogues X, Diez-Perez A, Puig-Domingo M, Mauricio D, Prieto-Alhambra D. Insulin use and Excess Fracture Risk in Patients with Type 2 Diabetes: A Propensity-Matched cohort analysis. *Sci Rep* 2017; **7**: 3781 [PMID: 28630427 DOI: 10.1038/s41598-017-03748-z]

232 **Losada E**, Soldevila B, Ali MS, Martínez-Laguna D, Nogués X, Puig-Domingo M, Díez-Pérez A, Mauricio D, Prieto-Alhambra D. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study. *Osteoporos Int* 2018; **29**: 2079-2086 [PMID: 29860664 DOI: 10.1007/s00198-018-4581-y]

233 **Rocha A**, Martins LS, Malheiro J, Dores J, Santos C, Henriques C. Changes in bone mineral density following long-term simultaneous pancreas-kidney transplantation. *J Bone Miner Metab* 2016; **34**: 209-215 [PMID: 25837429 DOI: 10.1007/s00774-015-0657-3]

234 **Nikkel LE**, Iyer SP, Mohan S, Zhang A, McMahon DJ, Tanriover B, Cohen DJ, Ratner L, Hollenbeak CS, Rubin MR, Shane E, Nickolas TL; CURE Group (The Columbia University Renal Epidemiology Group). Pancreas-kidney transplantation is associated with reduced fracture risk compared with kidney-alone transplantation in men with type 1 diabetes. *Kidney Int* 2013; **83**: 471-478 [PMID: 23283136 DOI: 10.1038/ki.2012.430]

235 **Rubino F**, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE; Delegates of the 2nd Diabetes Surgery Summit. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. *Diabetes Care* 2016; **39**: 861-877 [PMID: 27222544 DOI: 10.2337/dc16-0236]

236 **Angrisani L**, Santonicola A, Iovino P, Vitiello A, Zundel N, Buchwald H, Scopinaro N. Bariatric Surgery and Endoluminal Procedures: IFSO Worldwide Survey 2014. *Obes Surg* 2017; **27**: 2279-2289 [PMID: 28405878 DOI: 10.1007/s11695-017-2666-x]

237 **Lalmohamed A**, de Vries F, Bazelier MT, Cooper A, van Staa TP, Cooper C, Harvey NC. Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study. *BMJ* 2012; **345**: e5085 [PMID: 22867649 DOI: 10.1136/bmj.e5085]

238 **Lu CW**, Chang YK, Chang HH, Kuo CS, Huang CT, Hsu CC, Huang KC. Fracture Risk After Bariatric Surgery: A 12-Year Nationwide Cohort Study. *Medicine (Baltimore)* 2015; **94**: e2087 [PMID: 26632892 DOI: 10.1097/MD.0000000000002087]

239 **Nakamura KM**, Haglind EG, Clowes JA, Achenbach SJ, Atkinson EJ, Melton LJ 3rd, Kennel KA. Fracture risk following bariatric surgery: a population-based study. *Osteoporos Int* 2014; **25**: 151-158 [PMID: 23912559 DOI: 10.1007/s00198-013-2463-x]

240 **Rousseau C**, Jean S, Gamache P, Lebel S, Mac-Way F, Biertho L, Michou L, Gagnon C. Change in fracture risk and fracture pattern after bariatric surgery: nested case-control study. *BMJ* 2016; **354**: i3794 [PMID: 27814663 DOI: 10.1136/bmj.i3794]

241 **Yu EW**, Lee MP, Landon JE, Lindeman KG, Kim SC. Fracture Risk After Bariatric Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. *J Bone Miner Res* 2017; **32**: 1229-1236 [PMID: 28251687 DOI: 10.1002/jbmr.3101]

242 **Lindeman KG**, Greenblatt LB, Rourke C, Bouxsein ML, Finkelstein JS, Yu EW. Longitudinal 5-Year Evaluation of Bone Density and Microarchitecture After Roux-en-Y Gastric Bypass Surgery. *J Clin Endocrinol Metab* 2018; **103**: 4104-4112 [PMID: 30219833 DOI: 10.1210/jc.2018-01496]

243 **Madeira E**, Madeira M, Guedes EP, Mafort TT, Moreira RO, de Mendonça LMC, Lima ICB, Neto LV, de Pinho PRA, Lopes AJ, Farias MLF. Impact of Weight Loss With Intragastric Balloon on Bone Density and Microstructure in Obese Adults. *J Clin Densitom* 2019; **22**: 279-286 [PMID: 29661687 DOI: 10.1016/j.jocd.2017.12.002]

244 **Vilarrasa N**, Fabregat A, Toro S, Gordejuela AG, Casajoana A, Montserrat M, Garrido P, López-Urdiales R, Virgili N, Planas-Vilaseca A, Simó-Servat A, Pujol J. Nutritional deficiencies and bone metabolism after endobarrier in obese type 2 patients with diabetes. *Eur J Clin Nutr* 2018; **72**: 1447-1450 [PMID: 29352218 DOI: 10.1038/s41430-017-0074-x]

245 **Gagnon C**, Schafer AL. Bone Health After Bariatric Surgery. *JBMR Plus* 2018; **2**: 121-133 [PMID: 30283897 DOI: 10.1002/jbm4.10048]

246 **Zhang Y**, Chen Q, Liang Y, Dong Y, Mo X, Zhang L, Zhang B. Insulin use and fracture risk in patients with type 2 diabetes: A meta-analysis of 138,690 patients. *Exp Ther Med* 2019; **17**: 3957-3964 [PMID: 31007738 DOI: 10.3892/etm.2019.7461]

247 **Wongdee K**, Krishnamra N, Charoenphandhu N. Derangement of calcium metabolism in diabetes mellitus: negative outcome from the synergy between impaired bone turnover and intestinal calcium absorption. *J Physiol Sci* 2017; **67**: 71-81 [PMID: 27671701 DOI: 10.1007/s12576-016-0487-7]

248 **Pittas AG**, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007; **92**: 2017-2029 [PMID: 17389701 DOI: 10.1210/jc.2007-0298]

249 **The NS**, Crandell JL, Lawrence JM, King IB, Dabelea D, Marcovina SM, D'Agostino RB Jr, Norris JM, Pihoker C, Mayer-Davis EJ. Vitamin D in youth with Type 1 diabetes: prevalence of insufficiency and association with insulin resistance in the SEARCH Nutrition Ancillary Study. *Diabet Med* 2013; **30**: 1324-1332 [PMID: 23909945 DOI: 10.1111/dme.12297]

250 **Camacho PM**, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. *Endocr Pract* 2016; **22**: 1-42 [PMID: 27662240 DOI: 10.4158/EP161435.GL]

251 **Kanis JA**, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 2013; **24**: 23-57 [PMID: 23079689 DOI: 10.1007/s00198-012-2074-y]

252 **Watts NB**, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012; **97**: 1802-1822 [PMID: 22675062 DOI: 10.1210/jc.2011-3045]

253 **Bolland MJ**, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. *Lancet Diabetes Endocrinol* 2018; **6**: 847-858 [PMID: 30293909 DOI: 10.1016/S2213-8587(18)30265-1]

254 **Ogata M**, Iwasaki N, Ide R, Takizawa M, Tanaka M, Tetsuo T, Sato A, Uchigata Y. Role of vitamin D in energy and bone metabolism in postmenopausal women with type 2 diabetes mellitus: A 6-month follow-up evaluation. *J Diabetes Investig* 2018; **9**: 211-222 [PMID: 28371517 DOI: 10.1111/jdi.12666]

255 **Jafari T**, Faghihimani E, Feizi A, Iraj B, Javanmard SH, Esmaillzadeh A, Fallah AA, Askari G. Effects of vitamin D-fortified low fat yogurt on glycemic status, anthropometric indexes, inflammation, and bone turnover in diabetic postmenopausal women: A randomised controlled clinical trial. *Clin Nutr* 2016; **35**: 67-76 [PMID: 25794439 DOI: 10.1016/j.clnu.2015.02.014]

256 **Mager DR**, Jackson ST, Hoffmann MR, Jindal K, Senior PA. Vitamin D<sub>3</sub> supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: Results of an open label randomized clinical trial. *Clin Nutr* 2017; **36**: 686-696 [PMID: 27302208 DOI: 10.1016/j.clnu.2016.05.012]

257 **Larsen AU**, Grimnes G, Jorde R. The effect of high-dose vitamin D<sub>3</sub> supplementation on bone mineral density in subjects with prediabetes. *Osteoporos Int* 2018; **29**: 171-180 [PMID: 28921338 DOI: 10.1007/s00198-017-4222-x]

258 **Tou JC**. Evaluating resveratrol as a therapeutic bone agent: preclinical evidence from rat models of osteoporosis. *Ann N Y Acad Sci* 2015; **1348**: 75-85 [PMID: 26200189 DOI: 10.1111/nyas.12840]

259 **Ornstrup MJ**, Harsløf T, Kjær TN, Langdahl BL, Pedersen SB. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. *J Clin Endocrinol Metab* 2014; **99**: 4720-4729 [PMID: 25322274 DOI: 10.1210/jc.2014-2799]

260 **Bo S**, Gambino R, Ponzo V, Cioffi I, Goitre I, Evangelista A, Ciccone G, Cassader M, Procopio M. Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial. *Nutr Diabetes* 2018; **8**: 51 [PMID: 30237505 DOI: 10.1038/s41387-018-0059-4]

261 **Bo S**, Ponzo V, Evangelista A, Ciccone G, Goitre I, Saba F, Procopio M, Cassader M, Gambino R. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. *Acta Diabetol* 2017; **54**: 499-507 [PMID: 28238190 DOI: 10.1007/s00592-017-0977-y]

262 **Dias PC**, Limirio PHJO, Linhares CRB, Bergamini ML, Rocha FS, Morais RB, Balbi APC, Hiraki KRN, Dechichi P. Hyperbaric Oxygen therapy effects on bone regeneration in Type 1 diabetes mellitus in rats. *Connect Tissue Res* 2018; **59**: 574-580 [PMID: 29378458 DOI: 10.1080/03008207.2018.1434166]

263 **Limirio PHJO**, da Rocha Junior HA, Morais RB, Hiraki KRN, Balbi APC, Soares PBF, Dechichi P. Influence of hyperbaric oxygen on biomechanics and structural bone matrix in type 1 diabetes mellitus rats. *PLoS One* 2018; **13**: e0191694 [PMID: 29451877 DOI: 10.1371/journal.pone.0191694]

264 Reorganized text. *JAMA Otolaryngol Head Neck Surg* 2015; **141**: 428 [PMID: 25996397 DOI: 10.1001/jama.282.7.637]

265 **Hill Gallant KM**, Gallant MA, Brown DM, Sato AY, Williams JN, Burr DB. Raloxifene prevents skeletal fragility in adult female Zucker Diabetic Sprague-Dawley rats. *PLoS One* 2014; **9**: e108262 [PMID: 25243714 DOI: 10.1371/journal.pone.0108262]

266 **Yoshii T**, Yamada M, Minami T, Tsunoda T, Sasaki M, Kondo Y, Satoh S, Terauchi Y. The Effects of Bazedoxifene on Bone, Glucose, and Lipid Metabolism in Postmenopausal Women With Type 2 Diabetes: An Exploratory Pilot Study. *J Clin Med Res* 2015; **7**: 762-769 [PMID: 26345606 DOI: 10.14740/jocmr2278w]

267 **Dagdelen S**, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. *Adv Ther* 2007; **24**: 1314-1320 [PMID: 18165214]

268 **Vestergaard P**, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? *Calcif Tissue Int* 2011; **88**: 209-214 [PMID: 21161194 DOI: 10.1007/s00223-010-9450-4]

269 **Schwartz AV**, Pavo I, Alam J, Disch DP, Schuster D, Harris JM, Krege JH. Teriparatide in patients with osteoporosis and type 2 diabetes. *Bone* 2016; **91**: 152-158 [PMID: 27374026 DOI: 10.1016/j.bone.2016.06.017]

270 **Lasco A**, Morabito N, Basile G, Atteritano M, Gaudio A, Giorgianni GM, Morini E, Faraci B, Bellone F, Catalano A. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis. *Calcif Tissue Int* 2016; **98**: 123-128 [PMID: 26498169 DOI: 10.1007/s00223-015-0075-5]

271 **Passeri E**, Benedini S, Costa E, Corbetta S. A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women. *Int J Endocrinol* 2015; **2015**: 352858 [PMID: 25873952 DOI: 10.1155/2015/352858]

272 **Napoli N**, Pannacciulli N, Vittinghoff E, Crittenden D, Yun J, Wang A, Wagman R, Schwartz AV. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. *Diabetes Metab Res Rev* 2018; **34**: e2991 [PMID: 29430796 DOI: 10.1002/dmrr.2991]

273 **Kondegowda NG**, Fenutria R, Pollack IR, Orthofer M, Garcia-Ocaña A, Penninger JM, Vasavada RC. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. *Cell Metab* 2015; **22**: 77-85 [PMID: 26094891 DOI: 10.1016/j.cmet.2015.05.021]

274 **Clark M**, Kroger CJ, Tisch RM. Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response. *Front Immunol* 2017; **8**: 1898 [PMID: 29312356 DOI: 10.3389/fimmu.2017.01898]

275 **Cosman F**, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. *N Engl J Med* 2016; **375**: 1532-1543 [PMID: 27641143 DOI: 10.1056/NEJMoa1607948]

276 **Tonks KT**, White CP, Center JR, Samocha-Bonet D, Greenfield JR. Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity. *J Clin Endocrinol Metab* 2017; **102**: 1112-1121 [PMID: 28324004 DOI: 10.1210/jc.2016-3282]

277 **Laurent MR**, Cook MJ, Gielen E, Ward KA, Antonio L, Adams JE, Decallonne B, Bartfai G, Casanueva FF, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Lean MEJ, Lee DM, Pendleton N, Punab M, Claessens F, Wu FCW, Vanderschueren D, Pye SR, O'Neill TW; EMAS Group. Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study. *Osteoporos Int* 2016; **27**: 3227-3237 [PMID: 27273111 DOI: 10.1007/s00198-016-3656-x]

278 **Frost M**, Balkau B, Hatunic M, Konrad T, Mingrone G, Højlund K. The relationship between bone turnover and insulin sensitivity and secretion: Cross-sectional and prospective data from the RISC cohort study. *Bone* 2018; **108**: 98-105 [PMID: 29305997 DOI: 10.1016/j.bone.2017.12.029]

279 **Kalimeri M**, Leek F, Wang NX, Koh HR, Roy NC, Cameron-Smith D, Kruger MC, Henry CJ, Totman JJ. Association of Insulin Resistance with Bone Strength and Bone Turnover in Menopausal Chinese-Singaporean Women without Diabetes. *Int J Environ Res Public Health* 2018; **15** [PMID: 29710852 DOI: 10.3390/ijerph15050889]

280 **Iglesias P**, Arrieta F, Piñera M, Botella-Carretero JI, Balsa JA, Zamarrón I, Menacho M, Díez JJ, Muñoz T, Vázquez C. Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. *Clin Endocrinol (Oxf)* 2011; **75**: 184-188 [PMID: 21521304 DOI: 10.1111/j.1365-2265.2011.04035.x]

281 **Reyes-García R**, Rozas-Moreno P, López-Gallardo G, García-Martín A, Varsavsky M, Avilés-Perez MD, Muñoz-Torres M. Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. *Acta Diabetol* 2013; **50**: 47-52 [PMID: 22042129 DOI: 10.1007/s00592-011-0347-0]

282 **Farr JN**, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. *J Bone Miner Res* 2014; **29**: 787-795 [PMID: 24123088 DOI: 10.1002/jbmr.2106]

283 **Bhattoa HP**, Onyeka U, Kalina E, Balogh A, Paragh G, Antal-Szalmas P, Kaplar M. Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50 years of age with type 2 diabetes mellitus: a case-control study. *Clin Rheumatol* 2013; **32**: 1161-1167 [PMID: 23588883 DOI: 10.1007/s10067-013-2254-y]

284 **Gaudio A**, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2012; **97**: 3744-3750 [PMID: 22855334 DOI: 10.1210/jc.2012-1901]

285 **Ardawi MS**, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. *Bone* 2013; **56**: 355-362 [PMID: 23845326 DOI: 10.1016/j.bone.2013.06.029]

286 **Shu A**, Yin MT, Stein E, Cremers S, Dworakowski E, Ives R, Rubin MR. Bone structure and turnover in type 2 diabetes mellitus. *Osteoporos Int* 2012; **23**: 635-641 [PMID: 21424265 DOI: 10.1007/s00198-011-1595-0]

287 **Huang YJ**, Huang TW, Chao TY, Sun YS, Chen SJ, Chu DM, Chen WL, Wu LW. Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome. *Oncotarget* 2017; **8**: 78144-78152 [PMID: 29100456 DOI: 10.18632/oncotarget.17839]

288 **van Lierop AH**, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. *Eur J Endocrinol* 2012; **166**: 711-716 [PMID: 22267280 DOI: 10.1530/EJE-11-1061]

289 **Gennari L**, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. *J Clin Endocrinol Metab* 2012; **97**: 1737-1744 [PMID: 22399511 DOI: 10.1210/jc.2011-2958]

290 **Razny U**, Goralska J, Zdzienicka A, Gruca A, Zapala B, Micek A, Dembinska-Kiec A, Solnica B, Malczewska-Malec M. High Fat Mixed Meal Tolerance Test Leads to Suppression of Osteocalcin Decrease in Obese Insulin Resistant Subjects Compared to Healthy Adults. *Nutrients* 2018; **10** [PMID: 30388806 DOI: 10.3390/nu10111611]

291 **Sarkar PD**, Choudhury AB. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. *Eur Rev Med Pharmacol Sci* 2013; **17**: 1631-1635 [PMID: 23832730]

292 **Akin O**, Göl K, Aktürk M, Erkaya S. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. *Gynecol Endocrinol* 2003; **17**: 19-29 [PMID: 12724015]

293 **Movahed A**, Larijani B, Nabipour I, Kalantarhormozi M, Asadipooya K, Vahdat K, Akbarzadeh S, Farrokhnia M, Assadi M, Amirinejad R, Bargahi A, Sanjdideh Z. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. *J Bone Miner Metab* 2012; **30**: 683-691 [PMID: 22752126 DOI: 10.1007/s00774-012-0367-z]

294 **Berberoglu Z**, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. *J Clin Endocrinol Metab* 2007; **92**: 3523-3530 [PMID: 17595249 DOI: 10.1210/jc.2007-0431]

295 **Cheung CL**, Tan KC, Lam KS, Cheung BM. The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: a structural equation modeling approach. *J Clin Endocrinol Metab* 2013; **98**: 3856-3863 [PMID: 23796564 DOI: 10.1210/jc.2013-2024]

296 **Duan P**, Yang M, Wei M, Liu J, Tu P. Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes. *Int J Endocrinol* 2017; **2017**: 8724869 [PMID: 28255300 DOI: 10.1155/2017/8724869]

**P-Reviewer:** Klimontov VV, Serhiyenko VA **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Endocrinology and Metabolism

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**

**Figure 1 Schematic representation of the anatomical distribution of bone marrow adipose tissue depots.** Both hyperglycemia and the antidiabetic drugs thiazolidinediones may induce marrow adipose tissue (MAT) expansion by increasing the expression of peroxisome proliferator-activated receptor genes, which in turn stimulates adipogenesis. rMAT: Regulated MAT (MAT depots that increase or decrease in response to different stimuli).

**Table 1 Bone turnover markers in prediabetes/insulin resistance and type 2 diabetes**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **BTM** | **Meaning** | **Pre-DM/IR** | **Ref.** | **T2D** | **Ref.** |
| CTX | Bone resorption | ↓ or ↔ | [136,276,277]; [278-280] | ↓ | [129,132,134,137,281-286] |
| TRAP | Bone resorption | ↑? | [287] | ↓ or ↔ | [281]; [132] |
| uNTX | Bone resorption |  |  | ↓ | [285] |
| Sclerostin | Inhibition of bone formation | ↑ | [65] | ↑ | [284,285,288,289] |
| OC | Bone formation | ↓ or ↔ | [128,276,277, 290]; [278, 280] | ↓ or ↔ | [129,132,134,283,285,286,291-293]; [281,294] |
| P1NP | Bone formation | ↓ or ↔ | [136,277]; [280] | ↓ or ↔ | [132,134,137,282,285,286]; [283, 88] |
| BAP | Bone formation | Direct association with IR | [295] | ↔ or ↓ or ↑ | [281,286,292,294]; [284]; [132] |
| ALP | Bone formation | ? | ? | ↔ or ↑ | [292,294]; [293] |
| OPG | Inhibition of bone resorption | ↑ | [296] | ↑ | [293,296] |

BTM: Bone turnover marker; pre-DM: Prediabetes; IR: Insulin resistance; T2D: Type 2 diabetes; CTX: Carboxy-terminal cross-linking telopeptide of type I collagen; OC: Osteocalcin; P1NP: Procollagen type 1 amino-terminal propeptide; TRAP: Tartrate-resistant acid phosphatase; uNTX: Urinary N-telopeptide of type I collagen; BAP: Bone-specific alkaline phosphatase; ALP: Alkaline phosphatase; OPG: Osteoprotegerin; ↑: Increased; ↓: Decreased; ↔: Similar to healthy controls; ?: Unknown.

**Table 2 Effects of diabetes and prediabetes on bone health**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **T1D** | **T2D** | **Prediabetes** |
| Fracture risk | ↑↑ | ↑ | ? |
| Bone mineral density | ↓ | ↔ or ↑ | ↔ or ↑ |
| Bone turnover | ↓ | ↓↓ | ↓? |
| Bone marrow adiposity | ↔ | ↑ | ↑? |
| Bone matrix - AGEs | ↑ | ↑ | ? |
| Microarchitecture/geometry | ↑ cortical porosity | ↑ cortical porosity | ↓ trabecular and cortical bone size |

AGEs: Advanced glycation endproducts; T1D: Type 1 diabetes; T2D: Type 2 diabetes; ↑: Increased; ↓: Decreased; ↔: Similar to healthy controls; ?: Unknown.